JP3038339B2
(ja)
*
|
1988-05-02 |
2000-05-08 |
ザイナクシス・テクノロジーズ・インコーポレーテッド |
バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
|
DE69032284T2
(de)
*
|
1989-03-21 |
1998-10-08 |
Vical Inc |
Expression von exogenen polynukleotidsequenzen in wirbeltieren
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US6214804B1
(en)
|
1989-03-21 |
2001-04-10 |
Vical Incorporated |
Induction of a protective immune response in a mammal by injecting a DNA sequence
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
US6706694B1
(en)
|
1990-03-21 |
2004-03-16 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US6228844B1
(en)
|
1991-11-12 |
2001-05-08 |
Vical Incorporated |
Stimulating vascular growth by administration of DNA sequences encoding VEGF
|
US5256641A
(en)
*
|
1990-11-01 |
1993-10-26 |
State Of Oregon |
Covalent polar lipid-peptide conjugates for immunological targeting
|
US5827819A
(en)
*
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
US5543389A
(en)
*
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization |
Covalent polar lipid-peptide conjugates for use in salves
|
US5543390A
(en)
*
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US6156304A
(en)
*
|
1990-12-20 |
2000-12-05 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Gene transfer for studying and treating a connective tissue of a mammalian host
|
US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
US7202225B1
(en)
*
|
1993-10-15 |
2007-04-10 |
Emanuele R Martin |
Therapeutic delivery compositions and methods of use thereof
|
US20020123476A1
(en)
*
|
1991-03-19 |
2002-09-05 |
Emanuele R. Martin |
Therapeutic delivery compositions and methods of use thereof
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
US5756353A
(en)
*
|
1991-12-17 |
1998-05-26 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol-and liposome-based delivery
|
US6627615B1
(en)
|
1991-12-17 |
2003-09-30 |
The Regents Of The University Of California |
Methods and compositions for in vivo gene therapy
|
AU3467193A
(en)
*
|
1991-12-17 |
1993-07-19 |
Regents Of The University Of California, The |
Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR)
|
US5858784A
(en)
*
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
JPH07503372A
(ja)
*
|
1992-01-23 |
1995-04-13 |
バイカル・インコーポレイテッド |
生体外遺伝子導入
|
US5885970A
(en)
*
|
1992-03-16 |
1999-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotides against human protein kinase C
|
DE69333434T2
(de)
*
|
1992-04-03 |
2005-03-03 |
The Regents Of The University Of California, Oakland |
Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
|
US6113946A
(en)
*
|
1992-04-03 |
2000-09-05 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system comprising dendrimer polycations
|
US5792751A
(en)
*
|
1992-04-13 |
1998-08-11 |
Baylor College Of Medicine |
Tranformation of cells associated with fluid spaces
|
US20020108136A1
(en)
*
|
1997-03-21 |
2002-08-08 |
Sri |
Transgenic animals produced by homologous sequence targeting
|
US6806084B1
(en)
*
|
1992-06-04 |
2004-10-19 |
The Regents Of The University Of California |
Methods for compositions for in vivo gene delivery
|
CA2134773A1
(en)
*
|
1992-06-04 |
1993-12-09 |
Robert J. Debs |
Methods and compositions for in vivo gene therapy
|
KR20030097604A
(ko)
*
|
1992-07-13 |
2003-12-31 |
유카리언, 인코포레이티드 |
세포의 세포내 구획으로 지질화된 면역글로불린을전달하기 위한 조성물, 지질화된 단백질 및 지질화된 항체
|
US20090191227A1
(en)
|
2007-05-23 |
2009-07-30 |
Vical Incorporated |
Compositions and Methods for Enhancing Immune Responses to Vaccines
|
US7105574B1
(en)
|
1999-03-26 |
2006-09-12 |
Vical Incorporated |
Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
|
US5334761A
(en)
*
|
1992-08-28 |
1994-08-02 |
Life Technologies, Inc. |
Cationic lipids
|
US5523389A
(en)
*
|
1992-09-29 |
1996-06-04 |
Isis Pharmaceuticals, Inc. |
Inhibitors of human immunodeficiency virus
|
US5329029A
(en)
*
|
1992-11-05 |
1994-07-12 |
Wan Barbara Y |
Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
|
US5552155A
(en)
*
|
1992-12-04 |
1996-09-03 |
The Liposome Company, Inc. |
Fusogenic lipsomes and methods for making and using same
|
US5705655A
(en)
*
|
1992-12-17 |
1998-01-06 |
Megabios Corporation |
Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
|
US5631237A
(en)
*
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5578709A
(en)
*
|
1993-03-09 |
1996-11-26 |
Middlesex Sciences, Inc. |
Macromolecular microparticles and methods of production
|
EP1624068A1
(de)
*
|
1993-06-01 |
2006-02-08 |
Life Technologies Inc. |
Genetische Impfung mit kationischen Lipidstoffen
|
US5578475A
(en)
*
|
1993-07-12 |
1996-11-26 |
Life Technologies, Inc. |
Composition and methods for transfecting eukaryotic cells
|
US5563111A
(en)
*
|
1993-08-03 |
1996-10-08 |
Kao Corporation |
Agricultural chemical composition comprising amine surfactants with at least one ester or amide linkage
|
US6348449B1
(en)
|
1993-09-21 |
2002-02-19 |
The Trustees Of The University Of Pennsylvania |
Methods of inducing mucosal immunity
|
KR960705798A
(ko)
*
|
1993-11-24 |
1996-11-08 |
벤자민 에프 맥그로우 |
피페라진의 양쪽친화성 유도체(amphiphilic derivatives of piperazine)
|
EP0730405A4
(de)
*
|
1993-11-24 |
1997-02-19 |
Megabios Corp |
Amphiphile guanidin-derivate
|
US5665879A
(en)
*
|
1993-11-24 |
1997-09-09 |
Megabios Corporation |
Amphiphilic derivatives of piperazine
|
US6613351B1
(en)
*
|
1993-12-20 |
2003-09-02 |
Biotech Tools S.A. |
Compound capable of introducing at least one molecule into a cell
|
US5674908A
(en)
|
1993-12-20 |
1997-10-07 |
Life Technologies, Inc. |
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
|
US5830686A
(en)
*
|
1994-01-13 |
1998-11-03 |
Calydon |
Tissue-specific enhancer active in prostate
|
US6057299A
(en)
*
|
1994-01-13 |
2000-05-02 |
Calydon, Inc. |
Tissue-specific enhancer active in prostate
|
US5928944A
(en)
*
|
1994-02-04 |
1999-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of adenoviral-medicated cell transfection
|
US6075012A
(en)
*
|
1994-02-11 |
2000-06-13 |
Life Technologies, Inc. |
Reagents for intracellular delivery of macromolecules
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US5962427A
(en)
|
1994-02-18 |
1999-10-05 |
The Regent Of The University Of Michigan |
In vivo gene transfer methods for wound healing
|
US5942496A
(en)
|
1994-02-18 |
1999-08-24 |
The Regent Of The University Of Michigan |
Methods and compositions for multiple gene transfer into bone cells
|
US6074840A
(en)
|
1994-02-18 |
2000-06-13 |
The Regents Of The University Of Michigan |
Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
|
US5763416A
(en)
|
1994-02-18 |
1998-06-09 |
The Regent Of The University Of Michigan |
Gene transfer into bone cells and tissues
|
US6995008B1
(en)
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5651981A
(en)
*
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
US5739118A
(en)
|
1994-04-01 |
1998-04-14 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
JPH10502333A
(ja)
*
|
1994-04-07 |
1998-03-03 |
プロティーンニックス カンパニー |
バソアクティブ・インテスティナル・ポリペプチド
|
AU2589095A
(en)
*
|
1994-05-16 |
1995-12-05 |
Washington University |
Cell membrane fusion composition and method
|
WO1995035301A1
(en)
*
|
1994-06-22 |
1995-12-28 |
Megabios Corporation |
Cationic amphiphiles
|
US5777153A
(en)
*
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
FR2722506B1
(fr)
*
|
1994-07-13 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucleiques, preparation et utilisations
|
DE4426429A1
(de)
*
|
1994-07-26 |
1996-02-01 |
Boehringer Ingelheim Int |
Verfahren zum Einführen von DNA in höhere eukaryotische Zellen
|
US7592317B1
(en)
*
|
1994-08-11 |
2009-09-22 |
The University Of Chicago |
Constitutive gene expression in conjuction with ionizing radiation
|
AUPM747694A0
(en)
*
|
1994-08-16 |
1994-09-08 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids and peptides
|
US5527928A
(en)
*
|
1994-09-30 |
1996-06-18 |
Nantz; Michael H. |
Cationic transport reagents
|
US5892071A
(en)
*
|
1994-09-30 |
1999-04-06 |
The Reagents Of The University Of California |
Cationic transport reagents
|
US5837533A
(en)
*
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
US5785992A
(en)
*
|
1994-09-30 |
1998-07-28 |
Inex Pharmaceuticals Corp. |
Compositions for the introduction of polyanionic materials into cells
|
US5753613A
(en)
*
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
US6911216B1
(en)
|
1994-10-12 |
2005-06-28 |
Genzyme Corporation |
Targeted delivery via biodegradable polymers
|
US5641665A
(en)
|
1994-11-28 |
1997-06-24 |
Vical Incorporated |
Plasmids suitable for IL-2 expression
|
US6331524B1
(en)
|
1994-12-09 |
2001-12-18 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
|
US5948767A
(en)
*
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
US5767099A
(en)
*
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
US5939401A
(en)
*
|
1994-12-09 |
1999-08-17 |
Genzyme Corporation |
Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
|
US5910487A
(en)
*
|
1994-12-09 |
1999-06-08 |
Genzyme Corporation |
Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
|
US5650096A
(en)
*
|
1994-12-09 |
1997-07-22 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5747471A
(en)
*
|
1994-12-09 |
1998-05-05 |
Genzyme Corporation |
Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
|
US6071890A
(en)
*
|
1994-12-09 |
2000-06-06 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
|
US5840710A
(en)
*
|
1994-12-09 |
1998-11-24 |
Genzyme Corporation |
Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
|
US5719131A
(en)
*
|
1994-12-09 |
1998-02-17 |
Genzyme Corporation |
Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
|
US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US6630455B1
(en)
|
1995-01-13 |
2003-10-07 |
Vanderbilt University |
Methods for inducing mucosal immune responses
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5929043A
(en)
|
1995-01-31 |
1999-07-27 |
Pangene Corporation |
Recombinase mediated DNA therapies
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
US6752987B1
(en)
|
1995-02-28 |
2004-06-22 |
The Regents Of The University Of California |
Adenovirus encoding human adenylylcyclase (AC) VI
|
CN1136920C
(zh)
|
1995-02-28 |
2004-02-04 |
加利福尼亚大学董事会 |
基因转移介导的血管形成疗法
|
US20030148968A1
(en)
*
|
1995-02-28 |
2003-08-07 |
Hammond H. Kirk |
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
|
US5962428A
(en)
*
|
1995-03-30 |
1999-10-05 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
US20040043971A1
(en)
*
|
1995-04-03 |
2004-03-04 |
Bone Care International, Inc. |
Method of treating and preventing hyperparathyroidism with active vitamin D analogs
|
US6242434B1
(en)
*
|
1997-08-08 |
2001-06-05 |
Bone Care International, Inc. |
24-hydroxyvitamin D, analogs and uses thereof
|
US20020183288A1
(en)
*
|
1995-04-03 |
2002-12-05 |
Bone Care International, Inc. |
Method for treating and preventing hyperparathyroidism
|
WO1996034109A1
(en)
*
|
1995-04-25 |
1996-10-31 |
Vical Incorporated |
Single-vial formulations of dna/lipid complexes
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5869040A
(en)
*
|
1995-06-07 |
1999-02-09 |
Biogen, Inc |
Gene therapy methods and compositions
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US6051429A
(en)
*
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
AU5862296A
(en)
*
|
1995-06-07 |
1996-12-30 |
Gen-Probe Incorporated |
Thiocationic lipids, pharmaceutical compositions and methods of use thereof
|
US5756352A
(en)
*
|
1995-06-07 |
1998-05-26 |
Gen-Probe Incorporated |
Thiocationic lipid-nucleic acid conjugates
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
US5739271A
(en)
*
|
1995-06-07 |
1998-04-14 |
Gen-Probe Incorporated |
Thiocationic lipids
|
US5705385A
(en)
*
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
CA2223179A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Bob Dale Brown |
Phosphonic acid-based cationic lipids
|
AU701106B2
(en)
|
1995-06-07 |
1999-01-21 |
Promega Biosciences, Inc. |
Novel carbamate-based cationic lipids
|
WO1996040961A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
AU723163B2
(en)
*
|
1995-06-07 |
2000-08-17 |
Tekmira Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5711964A
(en)
*
|
1995-06-07 |
1998-01-27 |
United States Of America |
Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
|
US5851548A
(en)
*
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5994315A
(en)
*
|
1995-06-07 |
1999-11-30 |
East Carolina University |
Low adenosine agent, composition, kit and method for treatment of airway disease
|
US5759519A
(en)
*
|
1995-06-07 |
1998-06-02 |
Gen-Probe Incorporated |
Method for the intracellular delivery of biomolecules using thiocationic lipids
|
DE19521412A1
(de)
*
|
1995-06-14 |
1996-12-19 |
Boehringer Mannheim Gmbh |
Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
|
US5931809A
(en)
*
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
EP0869937A4
(de)
*
|
1995-07-21 |
2004-07-21 |
Promega Biosciences Inc |
Amidbasierende kationische lipide
|
US6339173B1
(en)
|
1996-07-22 |
2002-01-15 |
Promega Biosciences, Inc. |
Amide-based cationic lipids
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
NO953680D0
(no)
*
|
1995-09-18 |
1995-09-18 |
Hans Prydz |
Cellesyklusenzymer
|
US6120794A
(en)
*
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
AU7078396A
(en)
*
|
1995-09-27 |
1997-04-30 |
Regents Of The University Of California, The |
Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin:polynucleotide transfection complexes
|
US5869715A
(en)
*
|
1995-09-27 |
1999-02-09 |
The Reagents Of The University Of California |
Polyfunctional cationic cytofectins
|
US6086913A
(en)
*
|
1995-11-01 |
2000-07-11 |
University Of British Columbia |
Liposomal delivery of AAV vectors
|
WO1997019675A2
(en)
*
|
1995-11-30 |
1997-06-05 |
Vical Incorporated |
Complex cationic lipids
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US6126964A
(en)
*
|
1996-01-04 |
2000-10-03 |
Mirus Corporation |
Process of making a compound by forming a polymer from a template drug
|
AUPN741696A0
(en)
*
|
1996-01-05 |
1996-01-25 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids ii
|
US7002027B1
(en)
*
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US6392069B2
(en)
*
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US6077834A
(en)
*
|
1996-02-09 |
2000-06-20 |
Cheng; Pi-Wan |
Receptor ligand-facilitated delivery of biologically active molecules
|
AU2214597A
(en)
*
|
1996-03-18 |
1997-10-10 |
California Institute Of Technology |
Methods for increasing or decreasing transfection efficiency
|
US5783566A
(en)
*
|
1996-05-10 |
1998-07-21 |
California Institute Of Technology |
Method for increasing or decreasing transfection efficiency
|
US5994317A
(en)
*
|
1996-04-09 |
1999-11-30 |
Vical Incorporated |
Quaternary cytofectins
|
US5798250A
(en)
*
|
1996-04-15 |
1998-08-25 |
Icn Pharmaceuticals, Inc. |
Facilitating hepatitus virus infection in cell culture using a membrane stressor
|
WO1997040679A1
(en)
*
|
1996-05-01 |
1997-11-06 |
Imarx Pharmaceutical Corp. |
Methods for delivering compounds into a cell
|
CA2253561A1
(en)
*
|
1996-05-08 |
1997-11-13 |
Nika Health Products Limited |
Cationic virosomes as transfer system for genetic material
|
WO1997042819A1
(en)
*
|
1996-05-13 |
1997-11-20 |
Alberto Haces |
Cationic lipids for transfection of negatively charged or neutral molecules into living cells
|
US5980935A
(en)
*
|
1996-05-15 |
1999-11-09 |
Kirpotin; Dmitri |
Cationic lipids and methods of use therefor
|
US6274136B1
(en)
|
1996-05-29 |
2001-08-14 |
University Of Southern California |
Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
|
US8323963B2
(en)
*
|
1996-05-29 |
2012-12-04 |
University Of Southern California |
Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
|
US5935936A
(en)
*
|
1996-06-03 |
1999-08-10 |
Genzyme Corporation |
Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US6093816A
(en)
|
1996-06-27 |
2000-07-25 |
Isis Pharmaceuticals, Inc. |
Cationic lipids
|
WO1998000554A1
(en)
*
|
1996-07-03 |
1998-01-08 |
Genetics Institute, Inc. |
Protease fmh-1, an ice/ced-like protease
|
CA2261887C
(en)
*
|
1996-07-23 |
2007-10-02 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with biologically-active compounds for use in salves
|
KR100507660B1
(ko)
*
|
1996-09-13 |
2005-08-10 |
리폭센 테크놀로지즈 리미티드 |
리포좀
|
US7384923B2
(en)
*
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
DE69723531T3
(de)
|
1996-10-01 |
2012-09-06 |
Geron Corp. |
Katalytische Untereinheit der menschlichen Telomerase
|
US5861397A
(en)
*
|
1996-10-03 |
1999-01-19 |
Vical Incorporated |
Piperazine based cytofectins
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
FR2754828B1
(fr)
*
|
1996-10-23 |
1998-12-24 |
Univ Toulouse |
Structure membranaire artificielle, procede et polymere pour sa preparation, procede de preparation de ce polymere, particule et film comprenant cette structure
|
CA2271325A1
(en)
*
|
1996-11-12 |
1998-05-22 |
The Regents Of The University Of California |
Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
|
US6210707B1
(en)
*
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
US5965441A
(en)
*
|
1996-11-13 |
1999-10-12 |
The General Hospital Coporation |
HSV/AAV hybrid amplicon vectors
|
EP0948609B1
(de)
|
1996-12-06 |
2005-03-16 |
Aventis Pharmaceuticals Inc. |
Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
|
US7008776B1
(en)
*
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
EP0958380A4
(de)
*
|
1996-12-06 |
2004-03-17 |
Univ California |
Makromolekul-lipid komplexe sowie verfahren zu deren herstellung und verwendung
|
US20020128240A1
(en)
*
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
US6527716B1
(en)
|
1997-12-30 |
2003-03-04 |
Altea Technologies, Inc. |
Microporation of tissue for delivery of bioactive agents
|
AU750451B2
(en)
*
|
1997-02-13 |
2002-07-18 |
Bone Care International, Inc. |
Targeted therapeutic delivery of vitamin D compounds
|
US20030129194A1
(en)
*
|
1997-02-13 |
2003-07-10 |
Bone Care International, Inc. |
Targeted therapeutic delivery of vitamin D compounds
|
FR2760193B1
(fr)
*
|
1997-02-28 |
1999-05-28 |
Transgene Sa |
Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US7112338B2
(en)
*
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US5965542A
(en)
*
|
1997-03-18 |
1999-10-12 |
Inex Pharmaceuticals Corp. |
Use of temperature to control the size of cationic liposome/plasmid DNA complexes
|
US5948653A
(en)
*
|
1997-03-21 |
1999-09-07 |
Pati; Sushma |
Sequence alterations using homologous recombination
|
US5925628A
(en)
*
|
1997-03-31 |
1999-07-20 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5912239A
(en)
*
|
1997-04-04 |
1999-06-15 |
Genzyme Corporation |
Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5958894A
(en)
*
|
1997-04-04 |
1999-09-28 |
Megabios Corporation |
Amphiphilic biguanide derivatives
|
US6235310B1
(en)
|
1997-04-04 |
2001-05-22 |
Valentis, Inc. |
Methods of delivery using cationic lipids and helper lipids
|
FR2761912B1
(fr)
*
|
1997-04-14 |
1999-07-02 |
Capsulis |
Procede destine a faire adherer un produit sur une surface
|
WO1998049321A2
(en)
*
|
1997-04-28 |
1998-11-05 |
Rhone-Poulenc Rorer S.A. |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
WO1998049350A1
(en)
*
|
1997-04-30 |
1998-11-05 |
Regents Of The University Of Minnesota |
In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
|
US5948925A
(en)
*
|
1997-05-06 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
|
US5952516A
(en)
*
|
1997-05-08 |
1999-09-14 |
Genzyme Corporation |
Cationic amphiphiles containing multiplesteroid lipophilic groups
|
US5942634A
(en)
*
|
1997-05-09 |
1999-08-24 |
Genzyme Corporation |
Cationic amphiphiles for cell transfections
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
US6287591B1
(en)
*
|
1997-05-14 |
2001-09-11 |
Inex Pharmaceuticals Corp. |
Charged therapeutic agents encapsulated in lipid particles containing four lipid components
|
US20030104044A1
(en)
*
|
1997-05-14 |
2003-06-05 |
Semple Sean C. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
EP1007099A4
(de)
*
|
1997-07-11 |
2004-11-24 |
Univ Brandeis |
Methode zur induktion von apoptose mittels senkung des thiamin-spiegels
|
US20090239940A1
(en)
*
|
1997-07-22 |
2009-09-24 |
Del Monte Federica |
Treating heart failure and ventricular arrhythmias
|
EP1007673B1
(de)
|
1997-07-30 |
2008-12-17 |
Emory University |
Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
AU8692598A
(en)
|
1997-08-04 |
1999-02-22 |
Calydon, Inc. |
A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
|
EP1004022A4
(de)
|
1997-08-08 |
2000-10-25 |
Newbiotics Inc |
Methoden und zusammensetzungen zum überwinden der resistenz gegen bio- und chemotherapie
|
ES2167939T3
(es)
|
1997-08-13 |
2002-05-16 |
Biontex Lab Gmbh |
Nuevas poliaminas, su preparacion y usos.
|
US6818627B1
(en)
*
|
1997-08-14 |
2004-11-16 |
The Trustees Of The University Of Pennsylvania |
Functional fragments of HIV-1 Vpr protein and methods of using the same
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US6884842B2
(en)
|
1997-10-14 |
2005-04-26 |
Alnis Biosciences, Inc. |
Molecular compounds having complementary surfaces to targets
|
US6875606B1
(en)
|
1997-10-23 |
2005-04-05 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Human α-7 nicotinic receptor promoter
|
US5998482A
(en)
*
|
1997-11-10 |
1999-12-07 |
David; Sunil A. |
Use of synthetic polycationic amphiphilic substances with fatty acid or hydrocarbon substituents as anti-sepsis agents
|
ATE550042T1
(de)
*
|
1997-11-20 |
2012-04-15 |
Vical Inc |
Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
|
DK1039931T3
(da)
*
|
1997-12-01 |
2005-08-08 |
Fang Fang |
Multivalente rekombinante antistoffer til at behandle HRV infektioner
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
FR2772047B1
(fr)
|
1997-12-05 |
2004-04-09 |
Ct Nat D Etudes Veterinaires E |
Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
EP1047774A1
(de)
*
|
1998-01-16 |
2000-11-02 |
California Pacific Medical Center Research Institute |
Verfahren und zusammensetzungen für den gentransfer
|
CN1192102C
(zh)
|
1998-01-23 |
2005-03-09 |
新生物生物公司 |
酶催化的治疗剂
|
US7462605B2
(en)
*
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6043390A
(en)
|
1998-04-03 |
2000-03-28 |
The Regents Of The University Of California |
Pentaerythritol lipid derivatives and nucleic-acid complexes
|
US6271209B1
(en)
*
|
1998-04-03 |
2001-08-07 |
Valentis, Inc. |
Cationic lipid formulation delivering nucleic acid to peritoneal tumors
|
CA2328483A1
(en)
|
1998-05-06 |
1999-11-11 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Inhibitors of nf-kb activation
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
CA2330025C
(en)
*
|
1998-05-29 |
2009-03-17 |
The Scripps Research Institute |
Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
|
US6726925B1
(en)
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6200598B1
(en)
*
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
US20040077603A1
(en)
*
|
1998-08-28 |
2004-04-22 |
Wilhelm Stoffel |
Synthetic tear fluid
|
AU5911899A
(en)
*
|
1998-09-09 |
2000-03-27 |
Genzyme Corporation |
Methylation of plasmid vectors
|
US6135976A
(en)
|
1998-09-25 |
2000-10-24 |
Ekos Corporation |
Method, device and kit for performing gene therapy
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
EP1129064B1
(de)
|
1998-11-12 |
2008-01-09 |
Invitrogen Corporation |
Transportreagentien
|
US6656498B1
(en)
*
|
1998-11-25 |
2003-12-02 |
Vanderbilt University |
Cationic liposomes for gene transfer
|
EP1133465B1
(de)
|
1998-11-25 |
2004-07-14 |
Gene Therapy Systems, Inc. |
Amphiphile polyamin verbindungen
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US20020032164A1
(en)
|
1998-12-30 |
2002-03-14 |
Dale Roderic M. K. |
Antimicrobial compounds and methods for their use
|
US6441156B1
(en)
*
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
US6627215B1
(en)
|
1998-12-30 |
2003-09-30 |
Oligos Etc. Inc. |
Devices for improved wound management
|
US7868162B2
(en)
|
1998-12-30 |
2011-01-11 |
Lakewood-Amedex, Inc. |
Antimicrobial and antiviral compounds and methods for their use
|
US6570003B1
(en)
*
|
2001-01-09 |
2003-05-27 |
Lexion Genetics Incorporated |
Human 7TM proteins and polynucleotides encoding the same
|
US20020038013A1
(en)
*
|
2000-02-04 |
2002-03-28 |
Gregory Donoho |
Novel human membrane proteins and polynucleotides encoding the same
|
AU776150B2
(en)
*
|
1999-01-28 |
2004-08-26 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
|
ATE224730T1
(de)
|
1999-02-25 |
2002-10-15 |
Von Strandmann Elke Pogge |
Mittel zur behandlung von pigmentierungsstörungen
|
JP2002538090A
(ja)
|
1999-03-03 |
2002-11-12 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
ワクチンおよび遺伝子治療組成物およびその作製および使用法
|
US7393548B2
(en)
*
|
1999-03-22 |
2008-07-01 |
J.P. M.E.D. Ltd. |
Nano oil in glycerin emulsion
|
JP2002539800A
(ja)
|
1999-03-24 |
2002-11-26 |
ジーン セラピー システムズ インコーポレーテッド |
転写活性のあるdna断片を製造する方法
|
ATE549032T1
(de)
*
|
1999-03-26 |
2012-03-15 |
Vical Inc |
Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6696424B1
(en)
|
1999-05-28 |
2004-02-24 |
Vical Incorporated |
Cytofectin dimers and methods of use thereof
|
DE60016205T2
(de)
*
|
1999-05-28 |
2005-12-01 |
Vical, Inc., San Diego |
Cytofectin-dimere und verfahren zu ihrer anwendung
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6943152B1
(en)
|
1999-06-10 |
2005-09-13 |
Merial |
DNA vaccine-PCV
|
US20010048940A1
(en)
*
|
1999-06-18 |
2001-12-06 |
Jennifer D. Tousignant |
Cationic amphiphile micellar complexes
|
FR2797402B1
(fr)
|
1999-07-15 |
2004-03-12 |
Biomerieux Stelhys |
Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
|
CA2378187C
(en)
|
1999-07-22 |
2011-09-13 |
Newbiotics, Inc. |
Methods for treating therapy-resistant tumors
|
US6683061B1
(en)
*
|
1999-07-22 |
2004-01-27 |
Newbiotics, Inc. |
Enzyme catalyzed therapeutic activation
|
US20030078499A1
(en)
*
|
1999-08-12 |
2003-04-24 |
Eppstein Jonathan A. |
Microporation of tissue for delivery of bioactive agents
|
US20050249794A1
(en)
*
|
1999-08-27 |
2005-11-10 |
Semple Sean C |
Compositions for stimulating cytokine secretion and inducing an immune response
|
AUPQ259399A0
(en)
*
|
1999-09-01 |
1999-09-23 |
Lustre Investments Pte Ltd |
Therapeutic agents
|
US20010034437A1
(en)
*
|
2000-01-06 |
2001-10-25 |
Walke D. Wade |
Novel human proteases and polynucleotides encoding the same
|
US20020049312A1
(en)
*
|
2000-05-23 |
2002-04-25 |
Turner C. Alexander |
Noel human thrombospondin-like proteins and polynucleotides encoding the same
|
US20020161214A1
(en)
*
|
2000-11-01 |
2002-10-31 |
Walke D. Wade |
Novel human proteases and polynucleotides encoding the same
|
US20080003673A1
(en)
*
|
1999-09-02 |
2008-01-03 |
Alejandro Abuin |
Novel human proteases and polynucleotides encoding the same
|
US20030166902A1
(en)
*
|
2001-02-20 |
2003-09-04 |
Yi Hu |
Novel human protease and polynucleotides encoding the same
|
US20050153323A1
(en)
*
|
2000-07-28 |
2005-07-14 |
Yi Hu |
Novel human proteases and polynucleotides encoding the same
|
US20030050464A1
(en)
*
|
2000-07-28 |
2003-03-13 |
Yi Hu |
Novel human proteases and polynucleotides encoding the same
|
US6716614B1
(en)
*
|
1999-09-02 |
2004-04-06 |
Lexicon Genetics Incorporated |
Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof
|
US6448388B1
(en)
|
2000-08-16 |
2002-09-10 |
Lexicon Genetics Incorporated |
Human proteases and polynucleotides encoding the same
|
EE200200127A
(et)
*
|
1999-09-09 |
2003-04-15 |
The Regents Of The University Of California |
Taksaanide toimetamine katioonsete liposoomidega angiogeensete veresoonte piirkonda
|
US6790660B1
(en)
*
|
2001-09-18 |
2004-09-14 |
Lexicon Genetics Incorporated |
Human kielin-like proteins and polynucleotides encoding the same
|
US6867291B1
(en)
*
|
2000-09-15 |
2005-03-15 |
Lexicon Genetics Incorporated |
Human hemicentin proteins and polynucleotides encoding the same
|
US6720173B1
(en)
|
1999-11-08 |
2004-04-13 |
Lexicon Genetics Incorporated |
Human kinase protein and polynucleotides encoding the same
|
US6511840B1
(en)
|
2000-06-15 |
2003-01-28 |
Lexicon Genetics Incorporated |
Human kinase proteins and polynucleotides encoding the same
|
US6541252B1
(en)
|
2000-05-19 |
2003-04-01 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US6586230B1
(en)
*
|
2000-10-27 |
2003-07-01 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US6759527B2
(en)
|
2001-03-20 |
2004-07-06 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US6579710B2
(en)
*
|
2000-12-12 |
2003-06-17 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US6841377B1
(en)
|
2001-06-13 |
2005-01-11 |
Lexicon Genetics Incorporated |
Human kinase and polynucleotides encoding the same
|
US20080050809A1
(en)
*
|
1999-09-28 |
2008-02-28 |
Alejandro Abuin |
Novel human kinases and polynucleotides encoding the same
|
US6797510B1
(en)
*
|
2001-05-24 |
2004-09-28 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US7892541B1
(en)
|
1999-09-30 |
2011-02-22 |
Tumor Biology Investment Group, Inc. |
Soluble epidermal growth factor receptor isoforms
|
US20080213878A1
(en)
*
|
1999-10-19 |
2008-09-04 |
Gregory Donoho |
Novel human membrane proteins and polynucleotides encoding the same
|
US6750054B2
(en)
|
2000-05-18 |
2004-06-15 |
Lexicon Genetics Incorporated |
Human semaphorin homologs and polynucleotides encoding the same
|
CA2390650A1
(en)
*
|
1999-11-12 |
2001-05-17 |
Lexicon Genetics Incorporated |
Novel human proteases and polynucleotides encoding the same
|
AU1920601A
(en)
*
|
1999-11-19 |
2001-05-30 |
Lexicon Genetics Incorporated |
Novel human secreted proteins and polynucleotides encoding the same
|
ES2170622B1
(es)
*
|
1999-12-03 |
2004-05-16 |
Consejo Superior De Investigaciones Cientificas |
Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
|
WO2001042287A2
(en)
*
|
1999-12-07 |
2001-06-14 |
Lexicon Genetics Incorporated |
Putative human g-protein coupled receptors
|
JP2004504005A
(ja)
*
|
1999-12-07 |
2004-02-12 |
レキシコン・ジェネティクス・インコーポレーテッド |
ヒト新規キナーゼタンパクおよびそれをコードするポリヌクレオチド
|
EP1263966A1
(de)
*
|
1999-12-13 |
2002-12-11 |
Lexicon Genetics Incorporated |
Neue menschliche transferaseproteine und dafür kodierende polynukleotide
|
US20030008813A1
(en)
*
|
1999-12-17 |
2003-01-09 |
Felgner Philip L. |
Intracellular protein delivery compositions and methods of use
|
WO2001046407A1
(en)
*
|
1999-12-22 |
2001-06-28 |
Lexicon Genetics Incorporated |
Polynucleotides encoding human protease homologs
|
WO2001046417A2
(en)
*
|
1999-12-22 |
2001-06-28 |
Lexicon Genetics Incorporated |
Human membrane proteins and polynucleotides encoding the same having homology to cd20 proteins and ige receptors
|
FR2802925B1
(fr)
*
|
1999-12-23 |
2002-03-22 |
Commissariat Energie Atomique |
Amphiphiles cationiques, leurs applications et leur procede de synthese
|
EP1255822A2
(de)
*
|
1999-12-27 |
2002-11-13 |
The Regents Of The University Of California |
Modifizierte adenylylcyclase vom typ vi für gentheraphie bei congestiven herzkrankheiten
|
CA2395636A1
(en)
*
|
1999-12-30 |
2001-07-12 |
Novartis Ag |
Novel colloid synthetic vectors for gene therapy
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
EP1248846A2
(de)
*
|
2000-01-18 |
2002-10-16 |
Lexicon Genetics Incorporated |
Menschliches kinaseprotein und dafür kodierende polynukleotide
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US6852705B2
(en)
|
2000-01-21 |
2005-02-08 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
US7078388B2
(en)
*
|
2000-01-21 |
2006-07-18 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
US20040002472A1
(en)
*
|
2000-01-21 |
2004-01-01 |
Audonnet Jean-Christophe Francis |
Vaccination or immunization using a prime-boost regimen
|
AU5311701A
(en)
*
|
2000-01-26 |
2001-08-20 |
Lexicon Genetics Inc |
Novel human neurexin-like proteins and polynucleotides encoding the same
|
JP2003535588A
(ja)
*
|
2000-01-28 |
2003-12-02 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒト酵素及び該酵素をコードするポリヌクレオチド
|
WO2001055394A1
(en)
*
|
2000-01-28 |
2001-08-02 |
Lexicon Genetics Incorporated |
Human membrane proteins and polynucleotides encoding the same
|
CA2399663A1
(en)
*
|
2000-02-04 |
2001-08-09 |
Lexicon Genetics Incorporated |
Novel human enzymes and polynucleotides encoding the same
|
EP1254369B1
(de)
|
2000-02-08 |
2010-10-06 |
Sangamo BioSciences, Inc. |
Zellen zur entdeckung von medikamenten
|
CA2399876A1
(en)
*
|
2000-02-11 |
2001-08-16 |
Lexicon Genetics Incorporated |
Human proteases and polynucleotides encoding the same
|
CN1184076C
(zh)
|
2000-02-16 |
2005-01-12 |
精工爱普生株式会社 |
喷墨打印机用墨盒
|
AU2001238503A1
(en)
*
|
2000-02-17 |
2001-08-27 |
Lexicon Genetics Incorporated |
Novel human thrombospondin repeat proteins and polynucleotides encoding the same
|
WO2001064903A2
(en)
*
|
2000-02-29 |
2001-09-07 |
Lexicon Genetics Incorporated |
Novel human transferase proteins and polynucleotides encoding the same
|
EP1259610A2
(de)
*
|
2000-02-29 |
2002-11-27 |
Lexicon Genetics Incorporated |
Humane transporterproteine und ihre entsprechende nucleinsäuren
|
WO2001066744A2
(en)
*
|
2000-03-06 |
2001-09-13 |
Lexicon Genetics Incorporated |
Human transporter proteins and polynucleotides encoding the same
|
EP1263967A2
(de)
|
2000-03-10 |
2002-12-11 |
Lexicon Genetics Incorporated |
Humane g-protein gekoppelte rezeptorkinasen und dafür kodierende polynucleotide
|
DE60126962T2
(de)
*
|
2000-03-13 |
2007-11-22 |
Lexicon Genetics Inc., The Woodlands |
Menschliche phospholipasen und diese kodierende polynukleotide
|
CN102151337B
(zh)
|
2000-03-13 |
2014-03-12 |
恩根尼公司 |
调节消化道蛋白表达的组合物和方法
|
CA2402530C
(en)
|
2000-03-13 |
2014-01-14 |
Cornell Research Foundation, Inc. |
Blocking leukocyte emigration and inflammation by interfering with cd99
|
CA2403636A1
(en)
*
|
2000-03-20 |
2001-09-27 |
Lexicon Genetics Incorporated |
Human secreted proteins and polynucleotides encoding the same
|
US20040033600A1
(en)
|
2001-03-21 |
2004-02-19 |
Palli Subba Reddy |
Ecdysone receptor-based inducible gene expression system
|
US20040102388A1
(en)
*
|
2000-03-22 |
2004-05-27 |
High Katherine A. |
Modified blood clotting factors and methods of use
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
US6767736B2
(en)
|
2000-04-03 |
2004-07-27 |
Lexicon Genetics Incorporated |
Human ion channel protein and polynucleotides encoding the same
|
JP2003532391A
(ja)
*
|
2000-04-12 |
2003-11-05 |
レキシコン・ジェネティクス・インコーポレーテッド |
ヒトメタロプロテアーゼ及び該タンパク質をコードするポリヌクレオチド
|
EP1274720A4
(de)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
Albumin enthaltende fusionsproteine
|
WO2001079299A1
(en)
|
2000-04-13 |
2001-10-25 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
EP1278551A2
(de)
*
|
2000-04-21 |
2003-01-29 |
Vical Incorporated |
Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
|
AU2001257195B2
(en)
|
2000-04-25 |
2006-10-05 |
Lexicon Pharmaceuticals, Inc. |
Novel human kinase proteins and polynucleotides encoding the same
|
EP1280909A2
(de)
*
|
2000-05-12 |
2003-02-05 |
Lexicon Genetics Incorporated |
Menschliche lipocalin homologe und dafür kodierende polynukleotide
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US6790667B1
(en)
|
2000-05-30 |
2004-09-14 |
Lexicon Genetics Incorporated |
Human mitochondrial proteins and polynucleotides encoding the same
|
CA2411101C
(en)
|
2000-06-05 |
2018-01-16 |
Brigham And Women's Hospital, Inc. |
A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
|
WO2001094583A2
(en)
*
|
2000-06-07 |
2001-12-13 |
Lexicon Genetics Incorporated |
Human transporter proteins and polynucleotides encoding the same
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
PT1295611E
(pt)
*
|
2000-06-20 |
2010-09-14 |
Dainippon Sumitomo Pharma Co |
Preparações para transferência de oligonucleótidos
|
CA2415761A1
(en)
*
|
2000-06-27 |
2002-01-03 |
Lexicon Genetics Incorporated |
Novel human gaba receptors and polynucleotides encoding the same
|
AU2001278956B2
(en)
*
|
2000-07-18 |
2007-04-05 |
Genzyme Corporation |
Stabilized 1alpha-hydroxy vitamin d
|
AU2002224553A1
(en)
*
|
2000-07-21 |
2002-02-05 |
Incyte Genomics, Inc. |
Human proteases
|
US6887685B1
(en)
|
2000-07-25 |
2005-05-03 |
Lexicon Genetics Incorporated |
Human thymosin protein and polynucleotides encoding the same
|
EP1305435B1
(de)
*
|
2000-07-27 |
2007-12-19 |
The Trustees Of The University Of Pennsylvania |
Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
|
US20020076780A1
(en)
*
|
2000-08-16 |
2002-06-20 |
Turner C. Alexander |
Novel human ion channel proteins and polynucleotides encoding the same
|
EP1311690B1
(de)
*
|
2000-08-22 |
2006-07-26 |
Lexicon Genetics Incorporated |
Menschliche proteasen und für diese kodierende polynukleotide
|
JP2004506447A
(ja)
*
|
2000-08-22 |
2004-03-04 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒト7tmタンパクおよびそれをコードするポリヌクレオチド
|
IL154596A0
(en)
|
2000-08-25 |
2003-09-17 |
Basf Plant Science Gmbh |
Plant polynucleotides encoding novel prenyl proteases
|
AU2001285326A1
(en)
*
|
2000-08-31 |
2002-03-13 |
Lexicon Genetics Incorporated |
Human kinase proteins and polynucleotides encoding the same
|
US7229790B2
(en)
*
|
2000-09-01 |
2007-06-12 |
Lexicon Pharmaceuticals, Inc. |
Human GABA transporter protein and polynucleotides encoding the same
|
AU2001293084A1
(en)
*
|
2000-09-27 |
2002-04-08 |
Lexicon Genetics Incorporated |
Human protease inhibitor proteins and polynucleotides encoding the same
|
AU2001293019B2
(en)
*
|
2000-09-27 |
2007-01-18 |
Lexicon Pharmaceuticals, Inc. |
Human ion-exchanger proteins and polynucleotides encoding the same
|
US6777232B1
(en)
|
2000-10-02 |
2004-08-17 |
Lexicon Genetics Incorporated |
Human membrane proteins and polynucleotides encoding the same
|
US8105825B2
(en)
|
2000-10-03 |
2012-01-31 |
Intrexon Corporation |
Multiple inducible gene regulation system
|
US20050059031A1
(en)
|
2000-10-06 |
2005-03-17 |
Quantum Dot Corporation |
Method for enhancing transport of semiconductor nanocrystals across biological membranes
|
WO2002031129A2
(en)
|
2000-10-12 |
2002-04-18 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
US7001763B1
(en)
|
2000-10-17 |
2006-02-21 |
Lexicon Genetics Incorporated |
Human semaphorin proteins and polynucleotides encoding the same
|
US6831059B2
(en)
|
2000-10-20 |
2004-12-14 |
Allergan, Inc. |
Compositions and methods for treating gonadotrophin related illnesses
|
AU2002232387A1
(en)
*
|
2000-10-27 |
2002-05-06 |
Invitrogen Corporation |
Method for introducing antisense oligonucleotides into eucaryotic cells
|
WO2002070705A2
(en)
*
|
2000-10-27 |
2002-09-12 |
Lexicon Genetics Incorporated |
Human 7tm proteins and polynucleotides encoding them
|
WO2002036633A2
(en)
*
|
2000-10-30 |
2002-05-10 |
Lexicon Genetics Incorporated |
Human 7tm proteins and polynucleotides encoding the same
|
US7060442B2
(en)
*
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
JP2004535154A
(ja)
*
|
2000-11-15 |
2004-11-25 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒト分泌タンパク質およびそれをコードするポリヌクレオチド
|
AU2002228633A1
(en)
*
|
2000-11-20 |
2002-06-03 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
PT1346059E
(pt)
*
|
2000-11-29 |
2012-06-01 |
Pci Biotech As |
Internalização fotoquímica para distribuição de moléculas no citosol
|
TWI255272B
(en)
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
CA2431007A1
(en)
*
|
2000-12-11 |
2002-07-18 |
Lexicon Genetics Incorporated |
Novel human kinase and polynucleotides encoding the same
|
US6583269B1
(en)
|
2000-12-18 |
2003-06-24 |
Lexicon Genetics Incorporated |
Human protease inhibitor and polynucleotides encoding the same
|
US6852844B1
(en)
|
2000-12-20 |
2005-02-08 |
Lexicon Genetics Incorporated |
Human protocadherin proteins and polynucleotides encoding the same
|
CA2432737A1
(en)
*
|
2000-12-20 |
2002-06-27 |
Lexicon Genetics Incorporated |
Human ion channel protein and polynucleotides encoding the same
|
AU2002246858A1
(en)
*
|
2000-12-27 |
2002-08-06 |
Lexicon Genetics Incorporated |
Human kinases and polynucleotides encoding the same
|
DE10064870B4
(de)
*
|
2000-12-27 |
2004-10-07 |
G.O.T. Gesellschaft Zur Therapieoptimierung Und Targeting Entwicklungs Mbh |
Schwefelhaltige Amphiphile für den Transfer von biologisch aktiven Molekülen in Zellen
|
IL155726A0
(en)
|
2000-12-28 |
2003-11-23 |
Wyeth Corp |
Recombinant protective protein from streptococcus pneumoniae
|
WO2002053753A2
(en)
*
|
2001-01-05 |
2002-07-11 |
Lexicon Genetics Incorporated |
Novel human lipase and polynucleotides encoding the same
|
WO2002053754A2
(en)
*
|
2001-01-08 |
2002-07-11 |
Lexicon Genetics Incorporated |
Human protease and polynucleotides encoding the same
|
WO2002056832A2
(en)
*
|
2001-01-19 |
2002-07-25 |
Newbiotics, Inc. |
Methods to treat autoimmune and inflammatory conditions
|
WO2002059287A2
(en)
*
|
2001-01-23 |
2002-08-01 |
Lexicon Genetics Incorporated |
Novel human kinases and polynucleotides encoding the same
|
US20020115846A1
(en)
*
|
2001-01-24 |
2002-08-22 |
Xuanchuan (Sean) Yu |
Novel human lipase and polynucleotides encoding the same
|
CA2369944A1
(en)
*
|
2001-01-31 |
2002-07-31 |
Nucleonics Inc. |
Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
|
US20020127674A1
(en)
*
|
2001-02-02 |
2002-09-12 |
Xuanchuan Yu |
Novel human transporter protein and polynucleotides encoding the same
|
CA2438133C
(en)
|
2001-02-20 |
2015-01-27 |
Rheogene, Inc. |
Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
CA2441444C
(en)
|
2001-02-20 |
2013-09-03 |
Rheogene Holdings, Inc. |
Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system
|
JP4955905B2
(ja)
|
2001-02-20 |
2012-06-20 |
イントレキソン コーポレーション |
キメラレチノイドx受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用
|
CA2445796C
(en)
*
|
2001-02-20 |
2014-09-16 |
Rheogene, Inc. |
Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
WO2002070665A2
(en)
|
2001-03-02 |
2002-09-12 |
The Rockefeller University |
Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
|
JP3929250B2
(ja)
*
|
2001-03-08 |
2007-06-13 |
株式会社ルネサステクノロジ |
半導体装置
|
WO2002072603A2
(en)
*
|
2001-03-12 |
2002-09-19 |
Lexicon Genetics Incorporated |
Novel human dectin proteins and polynucleotides encoding the same
|
WO2002072774A2
(en)
*
|
2001-03-12 |
2002-09-19 |
Lexicon Genetics Incorporated |
Novel human transporter proteins and polynucleotides encoding the same
|
JP2004535781A
(ja)
*
|
2001-03-12 |
2004-12-02 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトefgファミリータンパクおよびそれをコードするポリヌクレオチド
|
AU2002254174A1
(en)
*
|
2001-03-13 |
2002-09-24 |
Vical Incorporated |
Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
|
US6994995B1
(en)
|
2001-03-16 |
2006-02-07 |
Lexicon Genetics Incorporated |
Human synaptotagmin and polynucleotides encoding the same
|
US6613534B2
(en)
|
2001-03-20 |
2003-09-02 |
Wake Forest University Health Sciences |
MAP-2 as a determinant of metastatic potential
|
US7294511B2
(en)
|
2001-03-22 |
2007-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US6936469B2
(en)
*
|
2001-03-22 |
2005-08-30 |
Chromos Molecular Systems Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US20030186390A1
(en)
*
|
2001-03-22 |
2003-10-02 |
De Jong Gary |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
US20030096414A1
(en)
*
|
2001-03-27 |
2003-05-22 |
Invitrogen Corporation |
Culture medium for cell growth and transfection
|
US20040028651A1
(en)
*
|
2001-03-29 |
2004-02-12 |
Karrupiah Muthumani |
Composition and methods of using hiv vpr
|
ATE541937T1
(de)
*
|
2001-04-06 |
2012-02-15 |
Univ Chicago |
Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
JP2004524043A
(ja)
|
2001-04-06 |
2004-08-12 |
レキシコン・ジェネティクス・インコーポレーテッド |
新規ヒトキナーゼ及び該キナーゼをコードするポリヌクレオチド
|
WO2002081671A1
(en)
|
2001-04-06 |
2002-10-17 |
Lexicon Genetics Incorporated |
Novel human kinase and polynucleotides encoding the same
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
US6644173B2
(en)
*
|
2001-04-11 |
2003-11-11 |
Keuring, Incorporated |
Beverage filter cartridge holder
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
CA2443493A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Wyeth |
Surface proteins of streptococcus pyogenes
|
US6607895B2
(en)
|
2001-04-16 |
2003-08-19 |
Lexicon Genetics Incorporated |
Human adenylsuccinate synthetase and polynucleotides encoding the same
|
US20020165175A1
(en)
*
|
2001-04-17 |
2002-11-07 |
Xiaowu Liang |
Fast and enzymeless cloning of nucleic acid fragments
|
US20030077829A1
(en)
*
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
WO2002088313A2
(en)
*
|
2001-04-30 |
2002-11-07 |
Lexicon Genetics Incorporated |
Novel human nuclear transporters and polynucleotides encoding the same
|
AU2002256398A2
(en)
*
|
2001-04-30 |
2002-11-11 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
WO2002090517A2
(en)
*
|
2001-05-09 |
2002-11-14 |
Lexicon Genetics Incorporated |
Novel human kinases and polynucleotides encoding the same
|
US20020193585A1
(en)
*
|
2001-05-25 |
2002-12-19 |
Walke D. Wade |
Novel human transporter proteins and polynucleotides encoding the same
|
CA2448347C
(en)
|
2001-05-29 |
2010-09-21 |
Lexicon Genetics Incorporated |
Novel human hydroxylases and polynucleotides encoding the same
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
EP1406645A4
(de)
*
|
2001-06-14 |
2005-02-16 |
Lexicon Genetics Inc |
Neue humantransporterproteine und diese kodierende polynucleotide
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
KR100888566B1
(ko)
*
|
2001-06-20 |
2009-03-12 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
핵산 도입을 촉진시키는 방법
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
AU2002315393A1
(en)
|
2001-06-21 |
2003-01-08 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
ES2269736T3
(es)
|
2001-06-22 |
2007-04-01 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
Proteccion frente a la hepatitis mediada por abin.
|
WO2003000174A2
(en)
*
|
2001-06-26 |
2003-01-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions and methods for intracellular delivery
|
AU2002318186A1
(en)
*
|
2001-07-03 |
2003-01-21 |
Lexicon Genetics Incorporated |
Novel human kielin-like proteins and polynucleotides encoding the same
|
US20030207834A1
(en)
|
2001-07-10 |
2003-11-06 |
Dale Roderic M.K. |
Oligonucleotide-containing pharmacological compositions and their use
|
JP2005522192A
(ja)
|
2001-07-19 |
2005-07-28 |
パーラン セラピューティクス, インコーポレイテッド |
マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
JP2005509409A
(ja)
*
|
2001-08-08 |
2005-04-14 |
ジェンザイム・コーポレーション |
糖尿病および他の血糖疾患の治療方法
|
US20040143104A1
(en)
*
|
2001-08-08 |
2004-07-22 |
Wadsworth Samuel C. |
Methods of treating diabetes and other blood sugar disorders
|
WO2003016481A2
(en)
*
|
2001-08-14 |
2003-02-27 |
Lexicon Genetics Incorporated |
Novel human collagen proteins and polynucleotides encoding the same
|
DE60238143D1
(de)
|
2001-09-18 |
2010-12-09 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
EP2266396A3
(de)
|
2001-09-24 |
2011-06-15 |
Sangamo BioSciences, Inc. |
Modulation von stammzellen mittels zinkfingerproteinen
|
US7177763B2
(en)
*
|
2001-09-25 |
2007-02-13 |
Werner Keber |
Method and device for preventing unpermitted approach of airplanes to objects on the ground which are to be protected
|
JP2005532781A
(ja)
|
2001-09-26 |
2005-11-04 |
レオジーン・ホールディングス,インコーポレーテッド |
ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用
|
CA2820170C
(en)
*
|
2001-09-26 |
2016-07-05 |
Intrexon Corporation |
Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
AU2002362753B9
(en)
*
|
2001-10-05 |
2008-05-15 |
The Trustees Of The University Of Pennsylvania |
Compositions for and methods of treating and preventing sirs/sepsis
|
NZ577565A
(en)
|
2001-10-09 |
2010-10-29 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
AU2002348163A1
(en)
*
|
2001-11-02 |
2003-05-19 |
Intradigm Corporation |
Therapeutic methods for nucleic acid delivery vehicles
|
WO2004033620A2
(en)
|
2001-11-02 |
2004-04-22 |
Insert Therapeutics, Inc. |
Methods and compositions for therapeutic use of rna interference
|
US7488313B2
(en)
*
|
2001-11-29 |
2009-02-10 |
Boston Scientific Scimed, Inc. |
Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
JP2005513073A
(ja)
*
|
2001-12-14 |
2005-05-12 |
トランジェーヌ、ソシエテ、アノニム |
ポリヌクレオチドを細胞へトランスフェクションするための組成物の製造のためのリゾ脂質の使用
|
CA2470999C
(en)
*
|
2001-12-20 |
2017-02-21 |
Schering-Plough Corporation |
Syn3 compositions and methods
|
EP2277888A3
(de)
|
2001-12-21 |
2011-04-27 |
Human Genome Sciences, Inc. |
Fusionsprotein von Albumin und Erythropoietin
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
WO2003057160A2
(en)
|
2002-01-02 |
2003-07-17 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2003205615B2
(en)
|
2002-01-10 |
2008-09-25 |
Universiteit Gent |
A novel splice variant of MyD88 and uses thereof
|
CA2475003A1
(en)
|
2002-02-01 |
2003-08-07 |
Sequitur, Inc. |
Double-stranded oligonucleotides
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
WO2003070905A2
(en)
*
|
2002-02-15 |
2003-08-28 |
Zycos, Inc. |
Electroporation methods for introducing bioactive agents into cells
|
AU2003230600B2
(en)
*
|
2002-03-05 |
2009-06-04 |
Transave, Inc. |
An inhalation system for prevention and treatment of intracellular infections
|
US8116860B2
(en)
*
|
2002-03-11 |
2012-02-14 |
Altea Therapeutics Corporation |
Transdermal porator and patch system and method for using same
|
US9918665B2
(en)
|
2002-03-11 |
2018-03-20 |
Nitto Denko Corporation |
Transdermal porator and patch system and method for using same
|
CA2478822C
(en)
|
2002-03-11 |
2016-07-12 |
Altea Therapeutics Corporation |
Transdermal drug delivery patch system, method of making same and method of using same
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
US20050240145A1
(en)
*
|
2002-04-30 |
2005-10-27 |
Neal Scott |
Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
|
CA2495787A1
(en)
*
|
2002-05-01 |
2003-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
EP1549352A4
(de)
*
|
2002-05-06 |
2005-07-27 |
Nucleonics Inc |
Verfahren zur abgabe von nukleinsäuren
|
US7598421B2
(en)
*
|
2002-05-08 |
2009-10-06 |
Ucl Biomedica Plc |
Materials for the delivery of biologically-active material to cells
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
EA200401565A1
(ru)
*
|
2002-05-24 |
2005-04-28 |
Неофарм, Инк. |
Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
|
EP1513853A2
(de)
*
|
2002-05-24 |
2005-03-16 |
Neopharm, Inc. |
Cardiolipin- zusamensetzungen, verfahren zu deren herstellung und verwendung
|
JP4563171B2
(ja)
|
2002-05-24 |
2010-10-13 |
シェーリング コーポレイション |
中和ヒト抗igfr抗体
|
ES2354607T3
(es)
|
2002-06-28 |
2011-03-16 |
Protiva Biotherapeutics Inc. |
Procedimiento y aparato para producir liposomas.
|
AU2003261103A1
(en)
*
|
2002-07-02 |
2004-01-23 |
Uab Research Foundation |
Compounds promoting delivery of genes
|
ATE348633T1
(de)
|
2002-07-05 |
2007-01-15 |
Lipoxen Technologies Ltd |
Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
|
US7375093B2
(en)
|
2002-07-05 |
2008-05-20 |
Intrexon Corporation |
Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
WO2004011624A2
(en)
*
|
2002-07-31 |
2004-02-05 |
Nucleonics, Inc. |
Double stranded rna structures and constructs, and methods for generating and using the same
|
US20040034336A1
(en)
*
|
2002-08-08 |
2004-02-19 |
Neal Scott |
Charged liposomes/micelles with encapsulted medical compounds
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7135324B2
(en)
|
2002-09-04 |
2006-11-14 |
The University Of Connecticut |
Viral recombinases, related articles, and methods of use thereof
|
WO2004022708A2
(en)
*
|
2002-09-09 |
2004-03-18 |
The Brigham And Women's Hospital, Inc. |
Genes and proteins altering tau-related neurodegeneration
|
EP1575505A4
(de)
*
|
2002-09-10 |
2007-01-24 |
Vical Inc |
Codon-optimierte vakzine auf polynucleotid-basis gegen infektionen mit bacillus anthracis
|
CN1694959B
(zh)
|
2002-09-13 |
2013-09-18 |
雷普利瑟公司 |
非序列互补的抗病毒寡核苷酸
|
US20040053895A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
AU2003302226A1
(en)
*
|
2002-09-24 |
2004-06-30 |
University Of Kentucky Research Foundation |
Nanoparticle-based vaccine delivery system containing adjuvant
|
EP1549767A4
(de)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation der expression von forkhead-box o1a
|
US9809654B2
(en)
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
US20050277611A1
(en)
*
|
2002-10-16 |
2005-12-15 |
Neopharm, Inc. |
Cationic cardiolipin analoges and its use thereof
|
US6863731B2
(en)
*
|
2002-10-18 |
2005-03-08 |
Controls Corporation Of America |
System for deposition of inert barrier coating to increase corrosion resistance
|
JP3447009B1
(ja)
*
|
2002-10-29 |
2003-09-16 |
實 平垣 |
構築物用構成体およびその製造方法
|
KR101301653B1
(ko)
*
|
2002-10-29 |
2013-08-30 |
트랜세이브, 인코포레이티드 |
항감염제의 지속적인 방출
|
US7718189B2
(en)
*
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
CA2504929C
(en)
|
2002-11-05 |
2014-07-22 |
Charles Allerson |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
EP2336318B1
(de)
|
2002-11-13 |
2013-04-24 |
Genzyme Corporation |
Antisense-modulation von apolipoprotein-b-expression
|
ES2420914T3
(es)
|
2002-11-13 |
2013-08-27 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
EP1903056A3
(de)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
|
JP4917263B2
(ja)
*
|
2002-12-23 |
2012-04-18 |
バイカル インコーポレイテッド |
核酸/ブロックコポリマー/陽イオン性界面活性剤複合体を凍結乾燥する方法
|
EP1581201A4
(de)
*
|
2002-12-23 |
2011-03-30 |
Vical Inc |
Verfahren zur herstellung steriler arzneimittel auf polynukleotidbasis
|
PT2311848E
(pt)
|
2002-12-23 |
2013-10-03 |
Vical Inc |
Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
|
US20070269891A9
(en)
*
|
2003-01-13 |
2007-11-22 |
Yasunobu Tanaka |
Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells
|
US20040138154A1
(en)
*
|
2003-01-13 |
2004-07-15 |
Lei Yu |
Solid surface for biomolecule delivery and high-throughput assay
|
AU2004206250B8
(en)
*
|
2003-01-21 |
2009-09-17 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
|
US7304161B2
(en)
|
2003-02-10 |
2007-12-04 |
Intrexon Corporation |
Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
|
ES2400033T3
(es)
|
2003-02-11 |
2013-04-05 |
Antisense Therapeutics Ltd |
Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina
|
EP1594547A2
(de)
*
|
2003-02-14 |
2005-11-16 |
University Of South Florida Research Foundation, Inc. |
Chitosan-mikropartikel für ifn gen-anlieferung
|
US7456315B2
(en)
|
2003-02-28 |
2008-11-25 |
Intrexon Corporation |
Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
ATE479752T1
(de)
|
2003-03-07 |
2010-09-15 |
Alnylam Pharmaceuticals Inc |
Therapeutische zusammensetzungen
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US20040242502A1
(en)
*
|
2003-04-08 |
2004-12-02 |
Galenica Pharmaceuticals, Inc. |
Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
CA2522751A1
(en)
*
|
2003-04-16 |
2004-11-04 |
Wyeth Holdings Corporation |
Novel immunogenic compositions for the prevention and treatment of meningococcal disease
|
WO2004094595A2
(en)
|
2003-04-17 |
2004-11-04 |
Alnylam Pharmaceuticals Inc. |
MODIFIED iRNA AGENTS
|
WO2004093788A2
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US8080642B2
(en)
*
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
EP1628647A4
(de)
*
|
2003-05-22 |
2007-10-24 |
Molecular Transfer Inc |
Neue lipide zur transfektion von nukleinsäuren
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
US7355056B2
(en)
*
|
2003-06-04 |
2008-04-08 |
Canji, Inc. |
Transfection agents
|
JP4980716B2
(ja)
|
2003-06-12 |
2012-07-18 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
遺伝子サイレンシングに有用な保存されたhbv及びhcv配列
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
US20060078560A1
(en)
*
|
2003-06-23 |
2006-04-13 |
Neopharm, Inc. |
Method of inducing apoptosis and inhibiting cardiolipin synthesis
|
CN101291653B
(zh)
*
|
2003-07-16 |
2012-06-27 |
普洛体维生物治疗公司 |
脂质包封的干扰rna
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
AU2004263865B2
(en)
|
2003-08-08 |
2007-05-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US7330851B2
(en)
*
|
2003-08-18 |
2008-02-12 |
Eaglehawk, Limited |
Data security through dissembly of data elements or connections between elements
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
WO2005040388A2
(en)
*
|
2003-08-22 |
2005-05-06 |
Nucleonics Inc. |
Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
|
US7291604B2
(en)
|
2003-09-03 |
2007-11-06 |
The General Hospital Corporation |
Methods of treating restenosis
|
CA2551022C
(en)
*
|
2003-09-15 |
2013-06-04 |
Protiva Biotherapeutics, Inc. |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
US7425544B2
(en)
|
2003-09-18 |
2008-09-16 |
Eli Lilly And Company |
Modulation of eIF4E expression
|
ATE518960T1
(de)
|
2003-09-19 |
2011-08-15 |
Sangamo Biosciences Inc |
Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression
|
NZ546272A
(en)
|
2003-10-10 |
2009-05-31 |
Alchemia Oncology Pty Ltd |
The modulation of hyaluronan synthesis and degradation in the treatment of disease
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
AU2003284327A1
(en)
*
|
2003-10-22 |
2005-06-08 |
Neal Scott |
Charged liposomes/micelles with encapsulated medical compounds
|
US8016811B2
(en)
|
2003-10-24 |
2011-09-13 |
Altea Therapeutics Corporation |
Method for transdermal delivery of permeant substances
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
ITMI20032185A1
(it)
*
|
2003-11-12 |
2005-05-13 |
Chemi Spa |
Processo per la sintesi di lipidi cationici.
|
EP1689432B1
(de)
|
2003-11-17 |
2009-12-30 |
Genentech, Inc. |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
US20050107318A1
(en)
*
|
2003-11-17 |
2005-05-19 |
Samuel Wadsworth |
Methods of treating diabetes and other blood sugar disorders
|
JP4954550B2
(ja)
*
|
2003-12-19 |
2012-06-20 |
大日本住友製薬株式会社 |
新規な核酸導入法
|
SE0303588D0
(sv)
|
2003-12-30 |
2003-12-30 |
Bioactive Polymers Ab C O Lund |
Surface protection of exposed biological tissues
|
WO2005071080A2
(en)
|
2004-01-20 |
2005-08-04 |
Isis Pharmaceuticals, Inc. |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US7432057B2
(en)
*
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
AU2005214091B2
(en)
*
|
2004-02-24 |
2010-08-12 |
Abbvie B.V. |
Method for determining the risk of developing a neurological disease
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
DE602005023426D1
(de)
*
|
2004-03-25 |
2010-10-21 |
California Inst Of Techn |
Hybridisierungskettenreaktion
|
DK1730280T3
(en)
*
|
2004-03-26 |
2019-02-04 |
Curis Inc |
RNA interference modulators for hedgehog signaling and applications thereof
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
CA2561565C
(en)
|
2004-04-08 |
2013-11-26 |
Sangamo Biosciences, Inc. |
Methods for repression of phospholamban gene and modulating cardiac contractility
|
US20050260652A1
(en)
*
|
2004-04-15 |
2005-11-24 |
The General Hospital Corporation |
Compositions and methods that modulate RNA interference
|
US7429459B2
(en)
|
2004-04-20 |
2008-09-30 |
Galapagos N.V. |
Methods for identifying a compound that inhibits the procession of amyloid-beta protein production in a mammalian cell expressing APP and overexpressing a G-protein coupled receptor in the cell
|
ES2427177T3
(es)
|
2004-04-27 |
2013-10-29 |
Galapagos N.V. |
Métodos, agentes y ensayos de detección de compuestos para inducir diferenciación de células de mamífero no diferenciadas para dar lugar a osteoblastos
|
US7935510B2
(en)
*
|
2004-04-30 |
2011-05-03 |
Intrexon Corporation |
Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
US7303881B2
(en)
*
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
KR101223366B1
(ko)
|
2004-05-03 |
2013-01-16 |
헤르메스 바이오사이언스, 인코포레이티드 |
약물 전달에 유용한 리포좀
|
EP1766094A4
(de)
|
2004-05-18 |
2009-11-25 |
Vical Inc |
Grippevirusimpfstoffzusammensetzung und verwendungsverfahren
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
CA2569645C
(en)
|
2004-06-07 |
2014-10-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
WO2005121348A1
(en)
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
EP2256198A1
(de)
|
2004-06-14 |
2010-12-01 |
Galapagos N.V. |
Identifizierungsverfahren und Verbindungen für die Behandlung degenerativer und entzündlicher Erkrankungen
|
WO2005124342A2
(en)
|
2004-06-21 |
2005-12-29 |
Galapagos N.V. |
Methods and means for treatment of osteoarthritis
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
CA2572439A1
(en)
*
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
US20080299095A1
(en)
*
|
2004-07-09 |
2008-12-04 |
Bc Cancer Agency |
Nup98-Hox Fusions for Expansion of Hemopoietic Stem Cells
|
US7604798B2
(en)
*
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
US20090214588A1
(en)
|
2004-07-16 |
2009-08-27 |
Nabel Gary J |
Vaccines against aids comprising cmv/r-nucleic acid constructs
|
WO2006007712A1
(en)
*
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
|
MX2007001679A
(es)
|
2004-08-09 |
2007-05-23 |
Elan Pharm Inc |
Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
|
US7985581B2
(en)
|
2004-08-23 |
2011-07-26 |
Alnylam Pharmaceuticals, Inc. |
Multiple RNA polymerase III promoter expression constructs
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP1789095A2
(de)
|
2004-09-16 |
2007-05-30 |
Sangamo Biosciences Inc. |
Zusammensetzungen und verfahren zur proteinherstellung
|
ATE505541T1
(de)
|
2004-09-24 |
2011-04-15 |
Alnylam Pharmaceuticals Inc |
Targeting von zwischenprodukten zur gegenstrangreplikation von einzelstrangigen viren durch rnai
|
US9315862B2
(en)
|
2004-10-05 |
2016-04-19 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
US20090281025A1
(en)
*
|
2004-10-18 |
2009-11-12 |
Mount Sinai School Of Medicine Of New York University |
Inhibition of tumor growth and metastasis by atf2-derived peptides
|
EP1804771A2
(de)
*
|
2004-10-28 |
2007-07-11 |
Idexx Laboratories, Inc. |
Zusammensetzungen zur kontrollierten verabreichung pharmazeutisch aktiver zusammensetzungen
|
US20060147449A1
(en)
*
|
2004-11-15 |
2006-07-06 |
Brass Lawrence F |
Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
|
AU2005306533B2
(en)
*
|
2004-11-17 |
2012-05-31 |
Arbutus Biopharma Corporation |
siRNA silencing of apolipoprotein B
|
DE102004057303A1
(de)
*
|
2004-11-26 |
2006-06-01 |
Merck Patent Gmbh |
Stabile Kristallmodifikationen von DOTAP Chlorid
|
US20060134221A1
(en)
*
|
2004-12-03 |
2006-06-22 |
Vical Incorporated |
Methods for producing block copolymer/amphiphilic particles
|
EP2316942B1
(de)
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
WO2006086667A2
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
EP2314614B1
(de)
|
2005-02-28 |
2015-11-25 |
Sangamo BioSciences, Inc. |
Anti-angiogene Verfahren und Zusammensetzungen
|
US7727721B2
(en)
*
|
2005-03-08 |
2010-06-01 |
California Institute Of Technology |
Hybridization chain reaction amplification for in situ imaging
|
CN101175769A
(zh)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
用于调控血管完整性的方法和组合物
|
US20090062184A1
(en)
*
|
2005-03-24 |
2009-03-05 |
Dainippon Sumitomo Pharma Co., Ltd. |
Fine particulate preparation comprising complex of nucleic acid molecule and collagen
|
EP1866414B9
(de)
|
2005-03-31 |
2012-10-03 |
Calando Pharmaceuticals, Inc. |
Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
|
US20070026061A1
(en)
*
|
2005-05-25 |
2007-02-01 |
Nahid Ali |
Liposomal formulation and use thereof
|
EP2816118B1
(de)
|
2005-05-31 |
2018-10-17 |
The Regents of the University of Colorado, a body corporate |
Verfahren zur Bereitstellung von Genen
|
EP1896386B1
(de)
|
2005-06-08 |
2012-09-05 |
Cangene Corporation |
Hyaluronsäurebindende peptide fördern die immunabwehr gegen pathogene bakterien
|
CN101437539B
(zh)
*
|
2005-07-05 |
2013-10-02 |
康奈尔研究基金会(有限公司) |
通过干扰cd99l2阻断白细胞迁出和炎症
|
AU2006272634B2
(en)
|
2005-07-26 |
2013-01-24 |
Sangamo Therapeutics, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US7666584B2
(en)
*
|
2005-09-01 |
2010-02-23 |
Philadelphia Health & Education Coporation |
Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer
|
CA2620387C
(en)
|
2005-09-20 |
2018-09-18 |
Basf Plant Science Gmbh |
Methods for controlling gene expression using ta-sirna
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
US7312079B1
(en)
|
2005-10-06 |
2007-12-25 |
Lexicon Pharmaceuticals, Inc. |
Variants of FAM3C
|
WO2007044727A2
(en)
|
2005-10-07 |
2007-04-19 |
California Institute Of Technology |
Pkr activation via hybridization chain reaction
|
NZ598088A
(en)
|
2005-10-21 |
2013-09-27 |
Univ California |
C-kit oncogene mutations in melanoma
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
US8114440B2
(en)
|
2005-11-16 |
2012-02-14 |
Idexx Laboratories Inc. |
Pharmaceutical compositions for the administration of aptamers
|
US7754679B2
(en)
*
|
2005-11-16 |
2010-07-13 |
Idexx Laboratories, Inc. |
Pharmaceutical compositions for the administration of aptamers
|
JP2009516710A
(ja)
|
2005-11-21 |
2009-04-23 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
eIF4E−BP2の発現のモジュレート
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
EP3067047B1
(de)
|
2005-12-08 |
2022-04-20 |
Insmed Incorporated |
Antiinfektive zusammensetzungen auf lipidbasis zur behandlung von lungeninfekten
|
US10647960B2
(en)
*
|
2005-12-13 |
2020-05-12 |
The Trustees Of The University Of Pennsylvania |
Transcriptome transfer produces cellular phenotype conversion
|
US9149543B2
(en)
|
2005-12-15 |
2015-10-06 |
The Trustees Of The University Of Pennsylvania |
Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
WO2007073489A2
(en)
*
|
2005-12-22 |
2007-06-28 |
Trustees Of Boston University |
Molecules for gene delivery and gene therapy, and methods of use thereof
|
CA2632331C
(en)
|
2005-12-22 |
2015-02-10 |
Vib Vzw |
Molecules with a beta-aggregating region and their use in inducing protein aggregation
|
EP2422819B1
(de)
|
2006-01-26 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzung und deren Verwendungen in Bezug auf Huntingtin
|
WO2008001166A2
(en)
*
|
2006-02-07 |
2008-01-03 |
Council Of Scientific & Industrial Research |
Process for synthesis of glycomimicking cationic amphiphiles
|
JP2009525757A
(ja)
|
2006-02-10 |
2009-07-16 |
ザ ユニバーシティ オブ シンシナティ |
心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−1
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
BRPI0710884A2
(pt)
*
|
2006-04-24 |
2011-08-16 |
Shantha West Inc |
polipeptìdeo isolado, ácido nucléico, célula transformada, vetor, composição farmacêutica, kit, e, métodos para identificar uma célula que expressa um polipeptìdeo, de triagem para um distúrbio proliferativo da célula, para induzir ou aumentar uma resposta imune a um polipeptìdeo, para tratar um indivìduo tendo, ou em risco de ter, um tumor, para identificar um inibidor ou estimulador da expressão de um polipeptìdeo, e para triar um indivìduo tendo, ou em risco de ter, um distúrbio proliferativo da célula
|
MX2008014005A
(es)
|
2006-05-03 |
2009-01-27 |
Baltic Technology Dev Ltd |
Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
|
CA2960570C
(en)
|
2006-05-05 |
2018-05-08 |
Molecular Transfer, Inc. |
Lipids for transfection of eukaryotic cells
|
EP2213731B1
(de)
|
2006-05-25 |
2013-12-04 |
Sangamo BioSciences, Inc. |
Varianten von Foki Spaltungs-Halbdomänen
|
GB0610636D0
(en)
|
2006-05-30 |
2006-07-05 |
Univ London |
Materials and complexes for the delivery of biologically-active material to cells
|
US8357781B2
(en)
|
2006-06-01 |
2013-01-22 |
Janssen Alzheimer Immunotherapy |
Neuroactive fragments of APP
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US20080004410A1
(en)
*
|
2006-06-30 |
2008-01-03 |
Yu-Chin Lai |
Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP5072275B2
(ja)
|
2006-07-03 |
2012-11-14 |
テルモ株式会社 |
閉鎖小胞の分離方法、製剤の製造方法および評価方法
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
BRPI0714981A2
(pt)
*
|
2006-07-28 |
2013-08-13 |
Sanofi Aventis |
composiÇço, mÉtodo para fazer a mesma a qual compreende um inibidor que inibe a atividade de uma proteÍna do complexo iii, um veÍculo e um membro da superfamÍlia da fator de necrose de tumor, mÉtodo para conduzir um ensaio para determinar se um composto É um inibidor de atividade de supressço de tnf de uma proteÍna do complexo iii e uso de um composto
|
CA2666682C
(en)
|
2006-10-19 |
2014-07-08 |
Merck & Co., Inc. |
Anti-il-13r.alpha.1 antibodies and their uses thereof
|
ES2501947T3
(es)
|
2006-10-19 |
2014-10-02 |
Csl Limited |
Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
|
US8466154B2
(en)
*
|
2006-10-27 |
2013-06-18 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
AU2007355108B2
(en)
|
2006-11-27 |
2013-07-11 |
Patrys Limited |
Novel glycosylated peptide target in neoplastic cells
|
EP1938843A1
(de)
*
|
2006-12-19 |
2008-07-02 |
Novosom AG |
Lipide und Lipidanordnungen mit transfektionsverstärkenden Elementen
|
AR064642A1
(es)
*
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
EP2118118B1
(de)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Vermittelte zelluläre verabreichung von lna-oligonukleotiden
|
US20100093836A1
(en)
|
2007-01-29 |
2010-04-15 |
Isis Pharmaceuticals, Inc |
Compounds and methods for modulating protein expression
|
EP2112930B1
(de)
|
2007-02-21 |
2017-01-11 |
Vaccinex, Inc. |
Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen
|
ES2556380T3
(es)
|
2007-02-22 |
2016-01-15 |
Genentech, Inc. |
Procedimientos para detectar una enfermedad inflamatoria del intestino
|
PL2583978T3
(pl)
|
2007-02-23 |
2016-07-29 |
Prothena Biosciences Ltd Co |
Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
|
PT2118300E
(pt)
|
2007-02-23 |
2015-09-22 |
Univ California |
Prevenção e tratamento da doença sinucleinopática e amiloidogénica
|
US20080299182A1
(en)
*
|
2007-03-01 |
2008-12-04 |
Shuyuan Zhang |
Methods and formulations for topical gene therapy
|
WO2008106658A2
(en)
|
2007-03-01 |
2008-09-04 |
California Institute Of Technology |
TRIGGERED RNAi
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
DE102007015598A1
(de)
*
|
2007-03-29 |
2008-10-02 |
Heinrich-Heine-Universität Düsseldorf |
Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
|
WO2008124768A1
(en)
|
2007-04-09 |
2008-10-16 |
The General Hospital Corporation |
Hemojuvelin fusion proteins and uses thereof
|
WO2008137717A1
(en)
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
JP5475643B2
(ja)
|
2007-05-04 |
2014-04-16 |
マリーナ バイオテック,インコーポレイテッド |
アミノ酸脂質およびその使用
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
NZ597601A
(en)
|
2007-05-16 |
2013-04-26 |
Mat Malta Advanced Technologies Ltd |
Treatment and prevention of influenza
|
WO2008144562A1
(en)
|
2007-05-16 |
2008-11-27 |
California Institute Of Technology |
A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
|
CN104761466A
(zh)
|
2007-05-29 |
2015-07-08 |
英特拉克森公司 |
通过蜕皮素受体复合物调节外源性基因表达的手性二酰基肼配体
|
US20080312174A1
(en)
*
|
2007-06-05 |
2008-12-18 |
Nitto Denko Corporation |
Water soluble crosslinked polymers
|
MX2009013766A
(es)
|
2007-06-20 |
2010-02-01 |
Galapagos Nv |
Objetivos moleculares y compuestos, y metodos para identificar los mismos, utiles en el tratamiento de enfermedades degenerativas de los huesos y las articulaciones.
|
US20090069266A1
(en)
*
|
2007-06-27 |
2009-03-12 |
Northwestern University |
Methods and compositions for nucleic acid transfer into cells
|
JP5770471B2
(ja)
|
2007-07-12 |
2015-08-26 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
α−1,6−フコシルトランスフェラーゼ(FUT8)遺伝子発現を不活性化するための方法および組成物
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US8828960B2
(en)
*
|
2007-07-17 |
2014-09-09 |
Idexx Laboratories, Inc. |
Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
|
KR20100049084A
(ko)
|
2007-08-23 |
2010-05-11 |
인트렉손 코포레이션 |
질병 진단을 위한 방법 및 조성물
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8367815B2
(en)
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
JP2010538647A
(ja)
*
|
2007-09-17 |
2010-12-16 |
ローム アンド ハース カンパニー |
植物における生理的応答を改変するための組成物および方法
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
BRPI0817233A2
(pt)
|
2007-09-28 |
2012-11-06 |
Intrexon Corp |
construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas
|
EP2205741A2
(de)
|
2007-10-02 |
2010-07-14 |
Amgen Inc. |
ERHÖHUNG DES ERYTHROPOIETINSPIEGELS MITTELS VERWENDUNG VON MIT miRNA HYBRIDISIERBAREN NUKLEINSÄUREN UND VORLÄUFER DAVON
|
CA2697992C
(en)
|
2007-10-04 |
2017-08-22 |
Zymogenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
JP2010539993A
(ja)
*
|
2007-10-08 |
2010-12-24 |
イントレキソン コーポレーション |
遺伝子操作した樹状細胞および癌の治療のための使用
|
GB0720486D0
(en)
*
|
2007-10-19 |
2007-11-28 |
Univ Edinburgh |
Cationic lipids
|
EP2217721A4
(de)
*
|
2007-10-29 |
2013-01-09 |
Univ California |
Osteoarthritis-gentherapie
|
US8097712B2
(en)
|
2007-11-07 |
2012-01-17 |
Beelogics Inc. |
Compositions for conferring tolerance to viral disease in social insects, and the use thereof
|
DE102008016275A1
(de)
|
2008-03-28 |
2009-11-19 |
Biontex Laboratories Gmbh |
Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
|
EP2212425A2
(de)
|
2007-11-22 |
2010-08-04 |
Biontex Laboratories Gmbh |
Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems
|
DE102008023913A1
(de)
|
2008-05-16 |
2009-11-19 |
Biontex Laboratories Gmbh |
Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
|
DE102007056488A1
(de)
|
2007-11-22 |
2009-07-23 |
Biontex Laboratories Gmbh |
Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
|
AU2008340355B2
(en)
|
2007-12-04 |
2015-01-22 |
Tekmira Pharmaceuticals Corporation |
Targeting lipids
|
US9029524B2
(en)
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
WO2009075886A1
(en)
|
2007-12-11 |
2009-06-18 |
The Scripps Research Institute |
Compositions and methods related to mrna translational enhancer elements
|
US8779088B2
(en)
|
2007-12-17 |
2014-07-15 |
Marfl Ab |
Vaccine for the treatment of Mycobacterium related disorders
|
ES2535419T3
(es)
|
2007-12-27 |
2015-05-11 |
Protiva Biotherapeutics Inc. |
Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
|
CN102016059B
(zh)
|
2007-12-28 |
2014-10-22 |
依兰制药公司 |
淀粉样变性的治疗和预防
|
CA2715289C
(en)
|
2008-02-11 |
2019-12-24 |
Rxi Pharmaceuticals Corporation |
Modified rnai polynucleotides and uses thereof
|
US8497364B2
(en)
*
|
2008-02-27 |
2013-07-30 |
California Institute Of Technology |
Triggered RNAi
|
US20110045001A1
(en)
*
|
2008-03-28 |
2011-02-24 |
Biontex Laboratories Gmbh |
Transfection results of non-viral gene delivery systems by influencing of the innate immune system
|
BRPI0911332A2
(pt)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
composições e uso de inibidores de epas1
|
AU2009234266B2
(en)
|
2008-04-11 |
2015-08-06 |
Tekmira Pharmaceuticals Corporation |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
CA2721380A1
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Silencing of csn5 gene expression using interfering rna
|
JP5475753B2
(ja)
|
2008-04-15 |
2014-04-16 |
プロチバ バイオセラピューティクス インコーポレイティッド |
核酸送達用の脂質製剤
|
CN110075113A
(zh)
|
2008-04-17 |
2019-08-02 |
Pds生物科技公司 |
通过阳离子脂质的对映体刺激免疫应答
|
US20100021904A1
(en)
*
|
2008-05-21 |
2010-01-28 |
Pierce Niles A |
Shielded cross-linking probes
|
US20100021901A1
(en)
*
|
2008-05-22 |
2010-01-28 |
Peng Yin |
Compositions and methods for detecting analytes
|
US8241854B2
(en)
*
|
2008-05-22 |
2012-08-14 |
California Institute Of Technology |
Triggered RNAi
|
ATE550024T1
(de)
|
2008-05-30 |
2012-04-15 |
Univ Yale |
Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression
|
KR101802393B1
(ko)
|
2008-06-10 |
2017-11-28 |
상가모 테라퓨틱스, 인코포레이티드 |
Bax- 및 bak-결함 세포주들의 제조 방법 및 조성물
|
EP2303318A2
(de)
|
2008-06-20 |
2011-04-06 |
Wyeth LLC |
Zusammensetzungen und verfahren zur verwendung von orf 1358 von beta-hämolytischen streptokokken-stämmen
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
KR20160015400A
(ko)
|
2008-08-22 |
2016-02-12 |
상가모 바이오사이언스 인코포레이티드 |
표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
|
AU2009275387B2
(en)
|
2008-08-25 |
2010-07-08 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
AU2009290848A1
(en)
|
2008-09-11 |
2010-03-18 |
Galapagos Nv |
Method for identifying compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant Cystic Fibrosis transmembrane conductance regulator
|
CN108165548B
(zh)
|
2008-09-22 |
2022-10-14 |
菲奥医药公司 |
减小大小的自递送RNAi化合物
|
EP2743265B1
(de)
|
2008-10-09 |
2017-03-15 |
Arbutus Biopharma Corporation |
Verbesserte Aminolipide und Verfahren zur Freisetzung von Nukleinsäuren
|
SG196818A1
(en)
|
2008-10-16 |
2014-02-13 |
Marina Biotech Inc |
Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
|
NZ592368A
(en)
|
2008-11-05 |
2013-11-29 |
Wyeth Llc |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
WO2010065787A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
EP2370580B1
(de)
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
|
EP2352369B1
(de)
|
2008-12-04 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Genomänderung bei ratten mithilfe von zink-finger-nukleasen
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
FR2941152B1
(fr)
*
|
2009-01-20 |
2013-10-18 |
Centre Nat Rech Scient |
Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques.
|
CA2934285C
(en)
|
2009-02-04 |
2018-11-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
CA2752239C
(en)
|
2009-02-12 |
2021-03-30 |
Opko Curna, Llc |
Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
|
JP5766126B2
(ja)
|
2009-02-12 |
2015-08-19 |
クルナ・インコーポレーテッド |
脳由来神経栄養因子(bdnf)関連疾病の、bdnfに対する天然アンチセンス転写物の抑制による治療
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
WO2010094733A2
(en)
|
2009-02-19 |
2010-08-26 |
Biofocus Dpi B.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
EP2398480A1
(de)
|
2009-02-19 |
2011-12-28 |
Galapagos N.V. |
Verfahren zur identifizierung und verbindungen zur diagnose und behandlung von mit entzündung einhergehenden krankheiten
|
US20120004160A1
(en)
|
2009-02-19 |
2012-01-05 |
Glaxo Group Ltd. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
EP2403946A4
(de)
|
2009-03-04 |
2012-11-14 |
|
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
|
CN102482677B
(zh)
|
2009-03-16 |
2017-10-17 |
库尔纳公司 |
通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
|
CN102549159B
(zh)
|
2009-03-17 |
2016-08-10 |
库尔纳公司 |
通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
|
US8993509B2
(en)
|
2009-03-31 |
2015-03-31 |
Robert Zimmerman |
Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
WO2010115841A1
(en)
|
2009-04-01 |
2010-10-14 |
Galapagos Nv |
Methods and means for treatment of osteoarthritis
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
EP2419511B1
(de)
|
2009-04-09 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Gezielte integration in stammzellen
|
WO2010117057A1
(ja)
|
2009-04-10 |
2010-10-14 |
協和発酵キリン株式会社 |
抗tim-3抗体を用いた血液腫瘍治療法
|
JP5822822B2
(ja)
|
2009-04-17 |
2015-11-24 |
ニューヨーク ユニバーシティ |
Tnfファミリー受容体を標的とし、tnf作用を拮抗するペプチド、その組成物、方法および使用
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
US20100273203A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Board Of Trustees Of The University Of Arkansas |
Methods and compositions for detecting metabolites
|
AU2010242598C1
(en)
|
2009-04-27 |
2015-02-05 |
Kyowa Kirin Co., Ltd. |
Anti-IL-3Ralpha antibody for use in treatment of blood tumor
|
US8044215B2
(en)
*
|
2009-04-29 |
2011-10-25 |
Juvaris Biotherapeutics, Inc. |
Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds
|
DK2424987T3
(en)
|
2009-05-01 |
2018-02-26 |
Curna Inc |
TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG
|
ES2609655T3
(es)
|
2009-05-06 |
2017-04-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
|
WO2010129799A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
|
CN102985548B
(zh)
|
2009-05-16 |
2016-10-26 |
崔坤元 |
用于递送治疗分子的包含阳离子两亲物和辅脂质的组合物
|
EP2432881B1
(de)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
|
WO2010135695A2
(en)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
ES2618576T3
(es)
|
2009-05-28 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
|
WO2010148010A1
(en)
|
2009-06-15 |
2010-12-23 |
4S3 Bioscience Inc. |
Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
WO2010151671A2
(en)
|
2009-06-24 |
2010-12-29 |
Curna, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
US20120237589A1
(en)
|
2009-07-09 |
2012-09-20 |
Marina Biotech, Inc. |
Amphoteric liposomes comprising imino lipids
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
JP5866283B2
(ja)
|
2009-07-28 |
2016-02-17 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
トリヌクレオチド反復疾患を治療するための方法および組成物
|
WO2011017315A2
(en)
|
2009-08-03 |
2011-02-10 |
Recombinetics, Inc. |
Methods and compositions for targeted gene modification
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
CA2769665A1
(en)
|
2009-08-05 |
2011-02-10 |
Opko Curna, Llc |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
US8410064B2
(en)
*
|
2009-08-24 |
2013-04-02 |
The Board Of Trustees Of The University Of Arkansas |
Classical cannabinoid metabolites and methods of use thereof
|
KR101892760B1
(ko)
|
2009-08-25 |
2018-08-28 |
큐알엔에이, 인크. |
IQGAP에 대한 천연 안티센스 전사체의 억제에 의한 GTPase 활성화 단백질을 함유하는 IQ 모티프(IQGAP)와 관련된 질환의 치료
|
AU2010289400B2
(en)
|
2009-09-02 |
2014-10-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
EP4089169A1
(de)
|
2009-10-12 |
2022-11-16 |
Larry J. Smith |
Verfahren und zusammensetzungen zum modulieren der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
|
US8962584B2
(en)
|
2009-10-14 |
2015-02-24 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Compositions for controlling Varroa mites in bees
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
WO2011056682A1
(en)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
|
WO2011056234A1
(en)
|
2009-11-06 |
2011-05-12 |
Fibrogen, Inc. |
Treatment for radiation-induced disorders
|
WO2011060233A1
(en)
|
2009-11-11 |
2011-05-19 |
The Trustees Of The University Of Pennsylvania |
Anti-tem1 antibodies and uses thereof
|
CN102741294A
(zh)
|
2009-11-30 |
2012-10-17 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
AU2010326132B9
(en)
|
2009-12-01 |
2014-10-02 |
Translate Bio, Inc. |
Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
|
JP2013513588A
(ja)
|
2009-12-11 |
2013-04-22 |
ジーンコード エーエス |
Gdnfファミリーリガンド(gfl)のミメティックまたはretシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法
|
NO2513310T3
(de)
|
2009-12-16 |
2018-03-31 |
|
|
US9068183B2
(en)
|
2009-12-23 |
2015-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
KR101853508B1
(ko)
|
2009-12-29 |
2018-06-20 |
큐알엔에이, 인크. |
종양 단백질 63 (p63)에 대한 천연 안티센스 전사체의 억제에 의한 p63에 관련된 질환의 치료
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
RU2612161C2
(ru)
|
2010-01-06 |
2017-03-02 |
Курна, Инк. |
Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
|
WO2011085347A2
(en)
|
2010-01-11 |
2011-07-14 |
Opko Curna, Llc |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
WO2011090971A2
(en)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
EP2526112B1
(de)
|
2010-01-22 |
2018-10-17 |
Dow AgroSciences LLC |
Gezielte genommodifikation
|
CN102782135A
(zh)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
|
EP2534173B1
(de)
|
2010-02-08 |
2019-09-11 |
Sangamo Therapeutics, Inc. |
Manipulierte spaltungs-halbdomänen
|
EP2534163B1
(de)
|
2010-02-09 |
2015-11-04 |
Sangamo BioSciences, Inc. |
Gezielte genommodifikation mit partiell einsträngigen donatormolekülen
|
CA2790506A1
(en)
|
2010-02-22 |
2011-08-25 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
PE20130214A1
(es)
|
2010-02-23 |
2013-03-11 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
MY163887A
(en)
|
2010-03-08 |
2017-11-15 |
Monsanto Technology Llc |
Polynucleotide molecules for gene regulations in plants
|
AU2011227050B2
(en)
|
2010-03-19 |
2016-12-08 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
US20130195800A1
(en)
|
2010-03-23 |
2013-08-01 |
Intrexon Corporation |
Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
|
EP2550001B1
(de)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna-interferenz bei augenerkrankungen
|
KR20180044433A
(ko)
|
2010-03-24 |
2018-05-02 |
알엑스아이 파마슈티칼스 코포레이션 |
진피 및 섬유증성 적응증에서의 rna 간섭
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
ES2640906T3
(es)
|
2010-03-24 |
2017-11-07 |
Institut National De La Sante Et De La Recherche Medicale |
Modelo primate de la familia de los cercopitécidos infectado por una cepa del VHB de genotipo humano
|
EP2550362B1
(de)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv-glycoproteine und rekombinante vektoren
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
US8883218B2
(en)
*
|
2010-03-26 |
2014-11-11 |
The Board Of Trustees Of The University Of Arkansas |
Anti-cancer nanoparticle compositions and methods of use
|
TWI644675B
(zh)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病
|
US8790621B2
(en)
|
2010-04-12 |
2014-07-29 |
Iowa State University Research Foundation, Inc. |
Nanoparticles and nanoparticle compositions
|
US20130116171A1
(en)
|
2010-04-16 |
2013-05-09 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using fgf
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
AU2011245987B2
(en)
|
2010-04-28 |
2016-12-15 |
Kyowa Hakko Kirin Co., Ltd |
Cationic lipid
|
WO2011139843A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Multi-sirna compositions for reducing gene expression
|
JP5902617B2
(ja)
|
2010-04-28 |
2016-04-13 |
協和発酵キリン株式会社 |
カチオン性脂質
|
MX343559B
(es)
|
2010-04-29 |
2016-11-10 |
Ionis Pharmaceuticals Inc |
Modulacion de la expresion de transtiretina.
|
MX342239B
(es)
|
2010-05-03 |
2016-09-21 |
Genentech Inc * |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
CN107988228B
(zh)
|
2010-05-03 |
2022-01-25 |
库尔纳公司 |
通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
JP5866106B2
(ja)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
インスリンを産生し分泌する腸内分泌細胞の製造方法
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
WO2011146121A1
(en)
|
2010-05-17 |
2011-11-24 |
Sangamo Biosciences, Inc. |
Novel dna-binding proteins and uses thereof
|
US8658780B2
(en)
|
2010-05-18 |
2014-02-25 |
California Institute Of Technology |
Triggered covalent probes for imaging and silencing genetic expression
|
DK2576783T3
(en)
|
2010-05-26 |
2018-03-12 |
Curna Inc |
TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
|
EP2580238A1
(de)
|
2010-06-09 |
2013-04-17 |
Zymogenetics, Inc. |
Dimere vstm3-fusionsproteine sowie zugehörige zusammensetzungen und verfahren
|
CA2802994A1
(en)
|
2010-06-17 |
2011-12-22 |
The United States Of America As Represented By The Secretary, National I Nstitutes Of Health |
Compositions and methods for treating inflammatory conditions
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
NZ606591A
(en)
|
2010-07-06 |
2015-02-27 |
Novartis Ag |
Cationic oil-in-water emulsions
|
HUE029284T2
(en)
|
2010-07-06 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Immunization of large mammals with low dose RNA
|
PT3243526T
(pt)
|
2010-07-06 |
2020-03-04 |
Glaxosmithkline Biologicals Sa |
Distribuição de arn para despoletar múltiplas vias imunitárias
|
MX2013000164A
(es)
*
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
|
NO2593547T3
(de)
|
2010-07-14 |
2018-04-14 |
|
|
US9834439B2
(en)
|
2010-07-20 |
2017-12-05 |
California Institute Of Technology |
Biomolecular self-assembly
|
US8962241B2
(en)
|
2010-07-20 |
2015-02-24 |
California Institute Of Technology |
Triggered molecular geometry based bioimaging probes
|
US8877438B2
(en)
|
2010-07-20 |
2014-11-04 |
California Institute Of Technology |
Self-assembled polynucleotide structure
|
WO2012015938A2
(en)
|
2010-07-27 |
2012-02-02 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
ES2850973T3
(es)
|
2010-08-23 |
2021-09-01 |
Wyeth Llc |
Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
|
MX2013002336A
(es)
|
2010-08-31 |
2013-03-18 |
Novartis Ag |
Liposomas pegilados para la liberacion de arn de codificacion de inmunogeno.
|
ES2585328T5
(es)
|
2010-09-10 |
2022-12-14 |
Wyeth Llc |
Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
|
WO2012035557A1
(en)
|
2010-09-14 |
2012-03-22 |
Council Of Scientific & Industrial Research |
Novel cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof
|
AU2011312562B2
(en)
|
2010-09-27 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
RU2624048C2
(ru)
|
2010-10-06 |
2017-06-30 |
Курна, Инк. |
Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
|
BR112013008700B8
(pt)
|
2010-10-11 |
2022-10-04 |
Novartis Ag |
Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
|
JP6049623B2
(ja)
|
2010-10-22 |
2016-12-21 |
カッパーアールエヌエー,インコーポレイテッド |
α‐L‐イズロニダーゼ(IDUA)への天然アンチセンス転写物の阻害によるIDUA関連疾患の治療
|
KR101913232B1
(ko)
|
2010-10-27 |
2018-10-30 |
큐알엔에이, 인크. |
인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
|
US20140134181A1
(en)
|
2010-11-05 |
2014-05-15 |
Kenneth E. Lipson |
Treatment Method For Lung Remodeling Diseases
|
JP6071893B2
(ja)
|
2010-11-23 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
Nanogへの天然アンチセンス転写物の阻害によるnanog関連疾患の治療
|
WO2012075337A2
(en)
|
2010-12-01 |
2012-06-07 |
Spinal Modulation, Inc. |
Directed delivery of agents to neural anatomy
|
WO2012078667A2
(en)
|
2010-12-06 |
2012-06-14 |
The Penn State Research Foundation |
Compositions and methods relating to proliferative diseases
|
EP3202897B1
(de)
|
2010-12-09 |
2020-04-15 |
Institut Pasteur |
Diagnostische verwendung eines fusionspolypeptids, das ein virales protein und ein mgmt-enzym enthält
|
US9095598B2
(en)
|
2010-12-28 |
2015-08-04 |
The Board Of Trustees Of The University Of Arkansas |
Stilbenoid derivatives and their uses
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
MX365647B
(es)
|
2011-02-02 |
2019-06-10 |
Excaliard Pharmaceuticals Inc |
El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
EP2492279A1
(de)
|
2011-02-25 |
2012-08-29 |
Laboratorios Del. Dr. Esteve, S.A. |
Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
|
US9402919B2
(en)
|
2011-03-04 |
2016-08-02 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9458456B2
(en)
|
2011-04-01 |
2016-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
CN105886506A
(zh)
|
2011-04-13 |
2016-08-24 |
Isis制药公司 |
Ptp1b 表达的反义调节
|
WO2012149515A2
(en)
*
|
2011-04-29 |
2012-11-01 |
Northwestern University |
Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
|
SG194957A1
(en)
*
|
2011-05-20 |
2013-12-30 |
Merck Patent Gmbh |
Stable crystal modifications of dotap chloride
|
AU2012261237B2
(en)
|
2011-05-24 |
2017-06-01 |
BioNTech SE |
Individualized vaccines for cancer
|
KR102128248B1
(ko)
|
2011-06-08 |
2020-07-01 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
CN103620036B
(zh)
|
2011-06-09 |
2016-12-21 |
库尔纳公司 |
通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
|
EP2691530B1
(de)
|
2011-06-10 |
2018-03-07 |
Oregon Health & Science University |
Cmv-glycoproteine und rekombinante vektoren
|
WO2012174476A2
(en)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
AU2012272970A1
(en)
|
2011-06-21 |
2014-02-06 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
|
EP2729125B1
(de)
|
2011-07-06 |
2017-12-13 |
GlaxoSmithKline Biologicals SA |
Öl-in-wasser-emulsionen mit nukleinsäuren
|
EP2729124B1
(de)
|
2011-07-06 |
2018-10-24 |
GlaxoSmithKline Biologicals SA |
Kationische öl-in-wasser-emulsionen
|
EP3332802A1
(de)
|
2011-07-06 |
2018-06-13 |
GlaxoSmithKline Biologicals SA |
Immunogene kombinationszusammensetzungen und ihre verwendung
|
JP6214530B2
(ja)
|
2011-07-15 |
2017-10-18 |
ザ ジェネラル ホスピタル コーポレイション |
転写活性化因子様エフェクターの組立て方法
|
EP2546358A1
(de)
|
2011-07-15 |
2013-01-16 |
Laboratorios Del. Dr. Esteve, S.A. |
Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
|
EP2568289A3
(de)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
|
US10760086B2
(en)
|
2011-09-13 |
2020-09-01 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10829828B2
(en)
|
2011-09-13 |
2020-11-10 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
US10806146B2
(en)
|
2011-09-13 |
2020-10-20 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
WO2013040057A1
(en)
|
2011-09-13 |
2013-03-21 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
EP3275461A1
(de)
|
2011-09-19 |
2018-01-31 |
Axon Neuroscience SE |
Proteinbasierte therapie und diagnose von tau-vermittelter pathologie im bereich von morbus alzheimer
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
AU2012312520A1
(en)
|
2011-09-20 |
2014-05-08 |
The University Of North Carolina At Chapel Hill |
Regulation of sodium channels by PLUNC proteins
|
KR101840512B1
(ko)
|
2011-09-20 |
2018-03-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Gcgr 발현의 안티센스 조절
|
CN108610423A
(zh)
|
2011-09-21 |
2018-10-02 |
桑格摩生物科学股份有限公司 |
调控转基因表达的方法和组合物
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
WO2013053765A1
(en)
|
2011-10-11 |
2013-04-18 |
Proyecto De Biomedicina Cima, S.L. |
A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
|
WO2013063313A1
(en)
|
2011-10-25 |
2013-05-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gccr expression
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
JP2013095755A
(ja)
|
2011-11-02 |
2013-05-20 |
Kyowa Hakko Kirin Co Ltd |
カチオン性脂質
|
HUE048622T2
(hu)
|
2011-11-18 |
2020-08-28 |
Alnylam Pharmaceuticals Inc |
RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére
|
ES2923787T3
(es)
|
2011-11-18 |
2022-09-30 |
Alnylam Pharmaceuticals Inc |
Agentes de iARN modificados
|
AU2012347605B2
(en)
*
|
2011-12-07 |
2017-09-21 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
US9061063B2
(en)
|
2011-12-07 |
2015-06-23 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
KR102007061B1
(ko)
|
2011-12-09 |
2019-08-02 |
앵스띠뛰 파스퇴르 |
다중 면역 스크리닝 분석
|
JP6182457B2
(ja)
|
2011-12-12 |
2017-08-16 |
協和発酵キリン株式会社 |
カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
|
CA2858694A1
(en)
|
2011-12-12 |
2013-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
Lipid nano particles comprising combination of cationic lipids
|
CA2859387A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
WO2013096679A1
(en)
|
2011-12-22 |
2013-06-27 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
US9464291B2
(en)
|
2012-01-06 |
2016-10-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
DK3381461T3
(da)
|
2012-01-09 |
2021-05-17 |
Serpin Pharma Llc |
Peptider og fremgangsmåder til anvendelse deraf
|
US9352042B2
(en)
|
2012-02-24 |
2016-05-31 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
KR102084539B1
(ko)
|
2012-02-29 |
2020-03-04 |
상가모 테라퓨틱스, 인코포레이티드 |
헌팅턴병을 치료하기 위한 방법 및 조성물
|
MX2018011291A
(es)
|
2012-03-09 |
2023-01-31 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas.
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
ES2694592T3
(es)
|
2012-03-15 |
2018-12-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
AU2013243951A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
US9783610B2
(en)
|
2012-04-27 |
2017-10-10 |
The Trustees Of The University Of Pennsylvania |
Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
|
CN104349783B
(zh)
|
2012-05-21 |
2018-07-13 |
英斯麦德公司 |
治疗肺部感染的系统
|
MX360866B
(es)
|
2012-05-24 |
2018-11-09 |
A B Seeds Ltd |
Composiciones y métodos para silenciar la expresión genética.
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
US20150267192A1
(en)
|
2012-06-08 |
2015-09-24 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
TR201816986T4
(tr)
|
2012-06-08 |
2019-01-21 |
Nitto Denko Corp |
Terapötik ajan iletim formülasyonlarına yönelik lipitler.
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
TW201726600A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
EP2872154B1
(de)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Verfahren und zusammensetzungen zur freisetzung von biologischen wirkstoffen
|
EP3196301B1
(de)
|
2012-07-11 |
2018-10-17 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von monogener krankheiten
|
EP2873732A4
(de)
|
2012-07-16 |
2016-03-23 |
Kyowa Hakko Kirin Co Ltd |
Pharmazeutische rnai-zusammensetzung mit unterdrückung der kras-genexpression
|
US9708607B2
(en)
|
2012-08-03 |
2017-07-18 |
Alnylam Pharmaceuticals, Inc. |
Modified RNAi agents
|
EP2698377A1
(de)
|
2012-08-17 |
2014-02-19 |
Laboratorios Del. Dr. Esteve, S.A. |
Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
|
DK2890780T3
(da)
|
2012-08-29 |
2020-09-21 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
US9365856B2
(en)
|
2012-09-14 |
2016-06-14 |
The Board Of Trustees Of The University Of Arkansas |
Methods of using a serum response factor isoform
|
US20160136159A1
(en)
|
2012-09-17 |
2016-05-19 |
Chemedest Ltd. |
Method for Treating Peripheral Neuropathy
|
EP2897639A4
(de)
|
2012-09-21 |
2016-05-04 |
Frank Bedu-Addo |
Verbesserte impfstoffzusammensetzungen und verfahren zur verwendung
|
WO2014059173A2
(en)
|
2012-10-10 |
2014-04-17 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
EP2906602B1
(de)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transkriptionsaktivator-like-effektor-lysinspezifische demethylase-1 (lsd1)-fusionsproteine
|
JP6484558B2
(ja)
|
2012-11-28 |
2019-03-13 |
バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーBiontech Rna Pharmaceuticals Gmbh |
癌ワクチンの組み合せ物
|
RU2675859C2
(ru)
|
2012-11-29 |
2018-12-25 |
Инсмед Инкорпорейтед |
Стабилизированные составы ванкомицина
|
BR112015013105B1
(pt)
|
2012-12-05 |
2022-02-08 |
Alnylam Pharmaceuticals, Inc |
Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
|
WO2014089541A2
(en)
|
2012-12-07 |
2014-06-12 |
Haplomics, Inc. |
Factor viii mutation repair and tolerance induction
|
ES2553782T3
(es)
|
2012-12-12 |
2015-12-11 |
The Broad Institute, Inc. |
Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
|
EP3031921A1
(de)
|
2012-12-12 |
2016-06-15 |
The Broad Institute, Inc. |
Ausgabe, bearbeitung und optimierung von systeme, verfahren und zusammensetzungen für sequenzmanipulation und therapeutische anwendungen
|
EP2931899A1
(de)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon
|
DK3064585T3
(da)
|
2012-12-12 |
2020-04-27 |
Broad Inst Inc |
Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
EP2840140B2
(de)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
CRISPR-Cas verwendetes Verfahren zur Mutation von Prokaryonten
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
US10683505B2
(en)
|
2013-01-01 |
2020-06-16 |
Monsanto Technology Llc |
Methods of introducing dsRNA to plant seeds for modulating gene expression
|
WO2014106838A2
(en)
|
2013-01-01 |
2014-07-10 |
A.B. Seeds Ltd. |
Methods of introducing dsrna to plant seeds for modulating gene expression
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
AU2014207618A1
(en)
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
EP2954042B1
(de)
|
2013-02-07 |
2017-12-06 |
The General Hospital Corporation |
Tale-transkriptionsaktivatoren
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
EP2953970A4
(de)
|
2013-02-08 |
2016-06-29 |
Misfolding Diagnostics Inc |
Transthyretinantikörper und verwendungen davon
|
CN105189542A
(zh)
|
2013-02-20 |
2015-12-23 |
瓦莱里昂治疗有限责任公司 |
用于治疗庞贝氏症的方法和组合物
|
EP2964665B1
(de)
|
2013-03-08 |
2018-08-01 |
Pfizer Inc |
Immunogene fusionspolypeptide
|
EP2968613B1
(de)
|
2013-03-11 |
2019-09-11 |
University of Florida Research Foundation, Inc. |
Freisetzung von card-protein zur behandlung von augenentzündungen
|
PL2968470T3
(pl)
|
2013-03-12 |
2021-05-31 |
The General Hospital Corporation |
Zmodyfikowane białka stanowiące substancję hamującą rozwój przewodów müllera (mis) i ich zastosowania do leczenia chorób
|
AU2014249015B2
(en)
|
2013-03-13 |
2020-04-16 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
JP6674888B2
(ja)
|
2013-03-13 |
2020-04-01 |
プロセナ バイオサイエンシーズ リミテッド |
タウ免疫療法
|
US10612019B2
(en)
|
2013-03-13 |
2020-04-07 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
PT2970974T
(pt)
|
2013-03-14 |
2017-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de componente do complemento c5 e métodos para a sua utilização
|
JP2016518812A
(ja)
|
2013-03-14 |
2016-06-30 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
線維症治療において有用な分子標的及び前記標的のインヒビター
|
BR112015022868B1
(pt)
|
2013-03-14 |
2023-05-16 |
Ethris Gmbh |
Composições de mrna de cftr e usos e métodos relacionados
|
JP2016522675A
(ja)
|
2013-03-14 |
2016-08-04 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
|
EP2972322B1
(de)
|
2013-03-14 |
2019-03-06 |
Galapagos NV |
Zielmoleküle und -verbindungen, und verfahren zur identifikation davon, zur behandlung von fibrotischen erkrankungen
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
EP3003295A1
(de)
|
2013-03-15 |
2016-04-13 |
The Penn State Research Foundation |
Zusammensetzungen und verfahren mit celecoxib und plumbagin zur behandlung von krebs
|
CA2905696A1
(en)
|
2013-03-15 |
2014-09-18 |
The Penn State Research Foundation |
Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer
|
EP2968606B1
(de)
|
2013-03-15 |
2020-10-07 |
Loma Linda University |
Behandlung von autoimmunerkrankungen
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
US10568328B2
(en)
|
2013-03-15 |
2020-02-25 |
Monsanto Technology Llc |
Methods and compositions for weed control
|
SG11201506875YA
(en)
|
2013-03-15 |
2015-09-29 |
Intrexon Corp |
Boron-containing diacylhydrazines
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
WO2014186585A2
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
SG10201804472YA
(en)
|
2013-05-22 |
2018-07-30 |
Alnylam Pharmaceuticals Inc |
SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP2999788B1
(de)
|
2013-05-22 |
2020-07-08 |
Northwestern University |
Rna-gerichtete dna-spaltung und genmanipulation durch das enzym cas9 aus neisseria meningitidis
|
SG11201510565TA
(en)
|
2013-05-22 |
2016-01-28 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
ES2862125T3
(es)
|
2013-06-13 |
2021-10-07 |
Antisense Therapeutics Ltd |
Terapia combinada para acromegalia
|
KR20160019553A
(ko)
|
2013-06-17 |
2016-02-19 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
DK3011029T3
(da)
|
2013-06-17 |
2020-03-16 |
Broad Inst Inc |
Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering
|
EP3597755A1
(de)
|
2013-06-17 |
2020-01-22 |
The Broad Institute, Inc. |
Freisetzung, verwendung und therapeutische anwendungen der crispr-cas-systeme und zusammensetzungen zur abzielung auf störungen und erkrankungen mit viralen komponenten
|
MX2015017312A
(es)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
WO2014210142A1
(en)
|
2013-06-25 |
2014-12-31 |
Temple University-Of The Commonwealth System Of Higher Education |
Cortical bone-derived stem cells
|
US9856472B2
(en)
|
2013-07-01 |
2018-01-02 |
California Institute Of Technology |
Small conditional RNAs
|
BR112016000555B1
(pt)
|
2013-07-19 |
2022-12-27 |
Monsanto Technology Llc |
Método para controlar uma infestação da espécie de leptinotarsa em uma planta, composição inseticida e construção de dna recombinante
|
US9850496B2
(en)
|
2013-07-19 |
2017-12-26 |
Monsanto Technology Llc |
Compositions and methods for controlling Leptinotarsa
|
US20160151284A1
(en)
|
2013-07-23 |
2016-06-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
CN105579582A
(zh)
|
2013-07-25 |
2016-05-11 |
埃克西奎雷股份有限公司 |
用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
US10568898B2
(en)
*
|
2013-08-13 |
2020-02-25 |
Northwestern University |
Lipophilic nanoparticles for drug delivery
|
CA3131284C
(en)
|
2013-08-28 |
2023-09-19 |
David Paschon |
Compositions for linking dna-binding domains and cleavage domains
|
WO2015031645A1
(en)
|
2013-08-28 |
2015-03-05 |
Washington University |
Monoclonal antibodies to human 14-3-3 epsilon and human 14-3-3 epsilon sv
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
CA2922838A1
(en)
|
2013-09-05 |
2015-03-12 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
KR101905278B1
(ko)
|
2013-09-08 |
2018-10-08 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
US10036020B2
(en)
|
2013-09-19 |
2018-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting JC virus (JCV)
|
AR097738A1
(es)
|
2013-09-23 |
2016-04-13 |
Alnylam Pharmaceuticals Inc |
Métodos para tratar o prevenir enfermedades asociadas con la transtiretina (ttr)
|
EP3049106A1
(de)
|
2013-09-25 |
2016-08-03 |
Zoetis Services LLC |
Divergente impfstoffzusammensetzung gegen pcv2b und verfahren zur verwendung
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
CN116836957A
(zh)
|
2013-10-17 |
2023-10-03 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
EP3060258A1
(de)
|
2013-10-22 |
2016-08-31 |
Shire Human Genetic Therapies, Inc. |
Mrna-therapie für phenylketonurie
|
EP3501605B1
(de)
|
2013-10-22 |
2023-06-28 |
Translate Bio, Inc. |
Mrna-therapie für argininosuccinat-synthase-mangel
|
CA2929533C
(en)
|
2013-11-04 |
2023-06-06 |
Monsanto Technology Llc |
Compositions and methods for controlling arthropod parasite and pest infestations
|
US9469650B2
(en)
|
2013-11-08 |
2016-10-18 |
Board Of Trustees Of The University Of Arkansas |
Melampomagnolide B derivatives
|
US9487536B2
(en)
|
2013-11-08 |
2016-11-08 |
Board Of Trustees Of The University Of Arkansas |
Melampomagnolide B derivatives
|
WO2015070212A1
(en)
|
2013-11-11 |
2015-05-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
RS62559B1
(sr)
|
2013-11-13 |
2021-12-31 |
Childrens Medical Center |
Nukleazom posredovana regulacija eksprimiranja gena
|
US10182988B2
(en)
|
2013-12-03 |
2019-01-22 |
Northwestern University |
Liposomal particles, methods of making same and uses thereof
|
JP6883987B2
(ja)
|
2013-12-04 |
2021-06-09 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
|
CN105874071B
(zh)
|
2013-12-09 |
2020-04-14 |
桑格摩生物科学股份有限公司 |
基因组工程化的方法和组合物
|
UA119253C2
(uk)
|
2013-12-10 |
2019-05-27 |
Біолоджикс, Інк. |
Спосіб боротьби із вірусом у кліща varroa та у бджіл
|
DK3079712T3
(da)
|
2013-12-11 |
2022-04-25 |
Massachusetts Gen Hospital |
Anvendelse af müllersk inhiberende substans- (mis) proteiner til kontraception og ovariereservebevarelse
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
EP3080271B1
(de)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systeme, verfahren und zusammensetzungen zur sequenzmanipulation mit optimierten funktionellen crispr-cas-systemen
|
MX2016007328A
(es)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
|
EP3798306A1
(de)
|
2013-12-12 |
2021-03-31 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-irna-zusammensetzungen und verfahren zur verwendung davon
|
RU2016128077A
(ru)
|
2013-12-12 |
2018-12-06 |
Те Брод Инститьют Инк. |
Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений
|
US10119136B2
(en)
|
2014-01-09 |
2018-11-06 |
Alnylam Pharmaceuticals, Inc. |
RNAi agents modified at the 4′-C position
|
MX368629B
(es)
|
2014-01-15 |
2019-10-08 |
Monsanto Technology Llc |
Metodos y composiciones para el control de malezas utilizando polinucleotidos de 5-enolpiruvilshikimato-3-fosfato sintasa (epsps).
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
SI3102673T1
(sl)
|
2014-02-03 |
2020-11-30 |
Sangamo Therapeutics, Inc. |
Postopki in sestavki za zdravljenje beta talasemije
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
KR20230152154A
(ko)
|
2014-02-11 |
2023-11-02 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법
|
US11053291B2
(en)
|
2014-02-19 |
2021-07-06 |
University Of Florida Research Foundation, Incorporated |
Delivery of Nrf2 as therapy for protection against reactive oxygen species
|
EP3110401A4
(de)
|
2014-02-25 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Lipidnanopartikel-impfstoffadjuvanzien und antigenfreisetzungssysteme
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
US9624498B2
(en)
|
2014-03-18 |
2017-04-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
BR112016022711A2
(pt)
|
2014-04-01 |
2017-10-31 |
Monsanto Technology Llc |
composições e métodos para controle de pragas de inseto
|
AU2015249312B2
(en)
|
2014-04-25 |
2021-07-29 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
EP3137119B1
(de)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von krebs mithilfe von einer nukleinsaüre gegen mdm2
|
WO2015168605A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
CN106456699B
(zh)
|
2014-05-05 |
2021-07-02 |
生物风险投资有限责任公司 |
作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
EP3139966B1
(de)
|
2014-05-08 |
2020-11-18 |
Sangamo Therapeutics, Inc. |
Zusammensetzungen zur verwendung bei der behandlung der huntington-krankheit
|
PT3142643T
(pt)
|
2014-05-15 |
2019-10-28 |
Insmed Inc |
Métodos para o tratamento de infeções mico bacterianas pulmonares não tuberculares
|
SG10202104570TA
(en)
|
2014-05-22 |
2021-06-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
AU2015266767A1
(en)
|
2014-05-30 |
2016-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods to treat latent viral infections
|
CA2953216C
(en)
|
2014-06-04 |
2020-12-22 |
Exicure, Inc. |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
BR112016029178A2
(pt)
|
2014-06-16 |
2017-10-17 |
Univ Johns Hopkins |
composições e métodos para a expressão de rnas guia de crispr usando o promotor h1
|
CA2953347A1
(en)
|
2014-06-23 |
2015-12-30 |
Monsanto Technology Llc |
Compositions and methods for regulating gene expression via rna interference
|
EP3161138A4
(de)
|
2014-06-25 |
2017-12-06 |
Monsanto Technology LLC |
Verfahren und zusammensetzungen zur zuführung von nukleinsäuren an pflanzenzellen und regulierung der genexpression
|
EP3160503B1
(de)
|
2014-06-26 |
2021-02-17 |
The Trustees of Columbia University in the City of New York |
Hemmung der serotoninexpression in enteroendokrinen darmzellenergebnissen bei der umwandlung in insulinpositive zellen
|
MX2017000646A
(es)
|
2014-07-15 |
2017-04-27 |
Juno Therapeutics Inc |
Celulas geneticamente modificadas para terapia celular adoptiva.
|
EP3169310A1
(de)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
|
WO2016014625A1
(en)
|
2014-07-22 |
2016-01-28 |
Board Of Trustees Of The University Of Arkansas |
Compositions and methods for selectively depleting senescent cells
|
EP3172222A4
(de)
|
2014-07-24 |
2018-03-21 |
Washington University |
Gegen strahlungsinduzierte moleküle gerichtete zusammensetzungen und verfahren zur verwendung davon
|
KR102330593B1
(ko)
|
2014-07-28 |
2021-11-26 |
에스케이이노베이션 주식회사 |
신규 이소프렌 신타아제 및 이를 이용한 이소프렌의 제조방법
|
RU2021123470A
(ru)
|
2014-07-29 |
2021-09-06 |
Монсанто Текнолоджи Ллс |
Композиции и способы борьбы с насекомыми-вредителями
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
ES2780904T3
(es)
|
2014-08-17 |
2020-08-27 |
Broad Inst Inc |
Edición genómica usando nickasas Cas9
|
EP3808846A1
(de)
|
2014-08-20 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Modifizierte doppelsträngige rna-wirkstoffe
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
EP3188799B1
(de)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von alterung und hauterkrankungen mit auf tyr oder mmp1 gerichteten nukleinsäuren
|
DK3191103T3
(da)
|
2014-09-10 |
2021-09-27 |
Univ Washington |
Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
EP3194570B1
(de)
|
2014-09-16 |
2021-06-30 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen für nukleasevermitteltes genom-engineering und korrektur bei hämotopoietischen stammzellen
|
EP3194359B1
(de)
|
2014-09-17 |
2020-04-08 |
Intrexon Corporation |
Borhaltige diacylhydrazinverbindungen
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
US10415037B2
(en)
|
2014-10-02 |
2019-09-17 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis B virus gene expression
|
SG11201702656WA
(en)
|
2014-10-06 |
2017-04-27 |
Exicure Inc |
Anti-tnf compounds
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016064832A1
(en)
|
2014-10-20 |
2016-04-28 |
The Curators Of The University Of Missouri |
Method for treating lymphedema
|
EP3904519A1
(de)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
EP3226889A4
(de)
|
2014-11-19 |
2018-11-21 |
The Trustees of Columbia University in the City of New York |
Osteocalcin zur behandlung von gebrechlichkeit im zusammenhang mit alterung
|
WO2016085986A1
(en)
|
2014-11-24 |
2016-06-02 |
Northwestern University |
High density lipoprptein nanoparticles for inflammation
|
US9981990B2
(en)
|
2014-12-03 |
2018-05-29 |
Bioventures, Llc |
Melampomagnolide B dimers
|
EP3231790B1
(de)
*
|
2014-12-08 |
2019-11-06 |
NOF Corporation |
Verfahren zur herstellung eines kationischen lipids
|
EP3230452A1
(de)
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Totführungen für crispr-transkriptionsfaktoren
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
EP3230451B1
(de)
|
2014-12-12 |
2021-04-07 |
The Broad Institute, Inc. |
Geschützte guide-rnas (pgrnas)
|
EP3233192B1
(de)
|
2014-12-15 |
2021-04-14 |
Washington University |
Zusammensetzungen und verfahren zur gezielten freisetzung von cytokinen
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
PL3256589T3
(pl)
|
2015-01-22 |
2022-02-21 |
Monsanto Technology Llc |
Kompozycje i sposoby kontrolowania leptinotarsa
|
EP3250691B9
(de)
|
2015-01-28 |
2023-08-02 |
Caribou Biosciences, Inc. |
Hybride crispr-dns/rns-polynukleotide und verfahren zur verwendung
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
AU2016221318B2
(en)
|
2015-02-19 |
2020-06-25 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
EP3265059A4
(de)
|
2015-03-03 |
2018-08-29 |
Cureport Inc. |
Liposomale pharmazeutische kombinationsformulierungen
|
WO2016141161A1
(en)
*
|
2015-03-03 |
2016-09-09 |
Cureport, Inc. |
Dual loaded liposomal pharmaceutical formulations
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
EP3069730A3
(de)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3277823B1
(de)
|
2015-04-03 |
2023-09-13 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzung und verfahren zur genomänderung von b-zellen
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
EP3283529B1
(de)
|
2015-04-17 |
2023-06-07 |
The General Hospital Corporation |
Wirkstoffe, systeme und verfahren zur behandlung von krebs
|
CA2984154A1
(en)
|
2015-05-01 |
2016-11-10 |
Onl Therapeutics, Inc. |
Peptide compositions and methods of use
|
WO2016179342A2
(en)
|
2015-05-06 |
2016-11-10 |
Alnylam Pharmaceuticals, Inc. |
Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
|
PT3298134T
(pt)
|
2015-05-16 |
2023-08-18 |
Genzyme Corp |
Edição génica de mutações intrónicas profundas
|
WO2016187512A1
(en)
|
2015-05-20 |
2016-11-24 |
Syracuse University |
Compositions and methods for enhancing peptide stability against protease digestion
|
WO2016187499A1
(en)
|
2015-05-20 |
2016-11-24 |
Syracuse University |
Improved glycemic control using intrinsic factor bound to a vitamin b12 conjugate of a glucagon-like peptide- 1 receptor agonist
|
CN108174607A
(zh)
|
2015-05-29 |
2018-06-15 |
朱诺治疗学股份有限公司 |
用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
MA50829A
(fr)
|
2015-06-01 |
2018-04-11 |
Sarepta Therapeutics Inc |
Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
|
CN107750125A
(zh)
|
2015-06-02 |
2018-03-02 |
孟山都技术有限公司 |
用于将多核苷酸递送至植物中的组合物和方法
|
WO2016196782A1
(en)
|
2015-06-03 |
2016-12-08 |
Monsanto Technology Llc |
Methods and compositions for introducing nucleic acids into plants
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
TW201710503A
(zh)
|
2015-06-12 |
2017-03-16 |
長庚醫療財團法人林口長庚紀念醫院 |
新穎多核苷酸、載體、醫藥組成物以及其用途
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
CA3012631A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017007813A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
US10450585B2
(en)
|
2015-07-13 |
2019-10-22 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
US10758612B2
(en)
|
2015-07-15 |
2020-09-01 |
Washington University |
Antibodies to tumor associated complex N-glycans with terminal GlcNAcβ residues and methods of use thereof
|
CN108350455A
(zh)
|
2015-07-29 |
2018-07-31 |
阿布特斯生物制药公司 |
用于使b型肝炎病毒基因表达沉默的组合物和方法
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
CN108366966A
(zh)
|
2015-08-24 |
2018-08-03 |
光环生物干扰疗法公司 |
用于调节基因表达的多核苷酸纳米颗粒及其用途
|
CA2996975C
(en)
|
2015-08-28 |
2022-02-15 |
Serpin Pharma, Llc |
Methods for treatment of diseases
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP3350328A1
(de)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Gegen patatin-like-phospholipasedomäne gerichtete polynukleotidmittel mit 3 (pnpla3) und verfahren zur verwendung davon
|
EP3352800B1
(de)
|
2015-09-24 |
2022-01-05 |
The University of North Carolina at Chapel Hill |
Verfahren und zusammensetzungen zur reduktion von metastasen
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
WO2017062835A2
(en)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
WO2017062855A1
(en)
|
2015-10-09 |
2017-04-13 |
Monsanto Technology Llc |
Novel rna-guided nucleases and uses thereof
|
AU2016334401A1
(en)
|
2015-10-10 |
2018-04-26 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
KR20180063255A
(ko)
|
2015-10-16 |
2018-06-11 |
입센 바이오팜 리미티드 |
캄프토테신 제약 조성물의 안정화
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
CA3024543A1
(en)
|
2015-10-22 |
2017-04-27 |
The Broad Institute, Inc. |
Type vi-b crispr enzymes and systems
|
IL310721A
(en)
|
2015-10-23 |
2024-04-01 |
President And Fellows Of Harvard College |
Nucleobase editors and their uses
|
ES2938883T3
(es)
|
2015-11-05 |
2023-04-17 |
Los Angeles Childrens Hospital |
Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
|
US20180319815A1
(en)
|
2015-11-05 |
2018-11-08 |
Board Of Trustees Of The University Of Arkansas |
Hetero-substituted cyclic lactone analogues and uses thereof
|
AU2016354590B2
(en)
|
2015-11-13 |
2023-11-23 |
Pds Biotechnology Corporation |
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
|
US10596248B2
(en)
|
2015-12-09 |
2020-03-24 |
Jingang Medicine (Australia) Pty Ltd |
Immunomodulating composition for treatment
|
EP3387129A1
(de)
|
2015-12-10 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen aus sterolregulatorischem element-bindendem protein (srep) chaperone (scap) irna und verfahren zur verwendung davon
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
EP3389677A4
(de)
|
2015-12-18 |
2019-05-22 |
Sangamo Therapeutics, Inc. |
Gezielte zerstörung des t-zell-rezeptors
|
WO2017106537A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the mhc cell receptor
|
CA3009131A1
(en)
|
2015-12-25 |
2017-06-29 |
Kyowa Hakko Kirin Co., Ltd. |
Compounds as cationic lipids and their use in nucleic acid delivery compositions
|
WO2017120589A1
(en)
|
2016-01-08 |
2017-07-13 |
Washington University |
Compositions comprising chemerin and methods of use thereof
|
AU2017207818B2
(en)
|
2016-01-15 |
2024-03-28 |
Regents Of The University Of Minnesota |
Methods and compositions for the treatment of neurologic disease
|
AU2017212653A1
(en)
|
2016-01-29 |
2018-07-19 |
Bioventures, Llc |
Triazole derivatives of melampomagnolide B and methods of use thereof
|
CA3011049A1
(en)
|
2016-02-02 |
2017-08-10 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
WO2017136558A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CA3011374A1
(en)
|
2016-02-05 |
2017-08-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
ES2754785T3
(es)
|
2016-02-22 |
2020-04-20 |
Caribou Biosciences Inc |
Procedimientos de modulación de resultados de reparación de ADN
|
GB201604235D0
(en)
|
2016-03-11 |
2016-04-27 |
Ucl Business Plc |
Lipids and complexes for the delivery of biologically-active material to cells
|
CN109071609A
(zh)
|
2016-03-24 |
2018-12-21 |
马凯特大学 |
定量鞭毛荧光标志物和标准品
|
US10213448B2
(en)
|
2016-03-25 |
2019-02-26 |
Novazoi Theranostics |
Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
|
MX2018012695A
(es)
|
2016-04-18 |
2019-06-20 |
Sarepta Therapeutics Inc |
Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido.
|
CA3026112A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
WO2017184768A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
US20200263190A1
(en)
|
2016-04-19 |
2020-08-20 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
CA3018991A1
(en)
|
2016-04-21 |
2017-10-26 |
Bioventures, Llc |
Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
|
KR102471787B1
(ko)
|
2016-05-02 |
2022-11-29 |
프로테나 바이오사이언시즈 리미티드 |
타우 인식 항체
|
PT3452507T
(pt)
|
2016-05-02 |
2022-12-20 |
Prothena Biosciences Ltd |
Imunoterapia anti-tau
|
JP7194985B2
(ja)
|
2016-05-02 |
2022-12-23 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
US11866700B2
(en)
|
2016-05-06 |
2024-01-09 |
Exicure Operating Company |
Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
US11708588B2
(en)
|
2016-06-16 |
2023-07-25 |
Adam Brian Robertson |
Gene editing
|
CN109642231A
(zh)
|
2016-06-17 |
2019-04-16 |
博德研究所 |
Vi型crispr直向同源物和系统
|
US20210222164A1
(en)
|
2016-06-29 |
2021-07-22 |
The Broad Institute, Inc. |
Crispr-cas systems having destabilization domain
|
WO2018006052A1
(en)
|
2016-06-30 |
2018-01-04 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
AU2017291727B2
(en)
|
2016-07-05 |
2021-07-08 |
California Institute Of Technology |
Fractional initiator hybridization chain reaction
|
JP2019520078A
(ja)
|
2016-07-05 |
2019-07-18 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
H1プロモーターを使用するcrisprガイドrnaの改良を含む組成物および方法
|
WO2018013840A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
JP2019524098A
(ja)
|
2016-07-15 |
2019-09-05 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
非分裂細胞のゲノム編集のための方法と組成物
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Plc |
Protein-based t-cell receptor knockdown
|
KR20230095129A
(ko)
|
2016-08-03 |
2023-06-28 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
US11878060B2
(en)
|
2016-08-07 |
2024-01-23 |
Novartis Ag |
mRNA-mediated immunization methods
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
CN110114461A
(zh)
|
2016-08-17 |
2019-08-09 |
博德研究所 |
新型crispr酶和系统
|
US20200283743A1
(en)
|
2016-08-17 |
2020-09-10 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
HUE056707T2
(hu)
|
2016-08-24 |
2022-03-28 |
Sangamo Therapeutics Inc |
Génexpresszió szabályozása szerkezeti nukleázok alkalmazásával
|
SG11201901364VA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases
|
US10815519B2
(en)
|
2016-08-30 |
2020-10-27 |
California Institute Of Technology |
Immunohistochemistry via hybridization chain reaction
|
US20210284998A1
(en)
*
|
2016-10-03 |
2021-09-16 |
Precision Nanosystems Inc. |
Compositions for Transfecting Resistant Cell Types
|
CA3038690A1
(en)
|
2016-10-05 |
2018-04-12 |
FUJIFILM Cellular Dynamics, Inc. |
Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
|
EP4190335A1
(de)
|
2016-10-13 |
2023-06-07 |
Juno Therapeutics, Inc. |
Immuntherapieverfahren und zusammensetzungen mit modulatoren des tryptophan-stoffwechselweges
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
EP3528852A4
(de)
|
2016-10-20 |
2020-06-03 |
Sangamo Therapeutics, Inc. |
Verfahren und zusammensetzungen zur behandlung von morbus fabry
|
EP3528827A4
(de)
|
2016-10-21 |
2020-11-04 |
Merck Sharp & Dohme Corp. |
Influenza-hämagglutinin-protein-impfstoffe
|
WO2018081388A1
(en)
|
2016-10-26 |
2018-05-03 |
Washington University |
Compositions comprising desaminotyrosine and uses thereof to enhance type i interferon stimulation
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
US10011848B2
(en)
|
2016-11-09 |
2018-07-03 |
City University Of Hong Kong |
System and method for delivery of substance into mammalian cells
|
EP3538660A1
(de)
|
2016-11-09 |
2019-09-18 |
Intrexon Corporation |
Konstrukte zur frataxinexpression
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
US11793833B2
(en)
|
2016-12-02 |
2023-10-24 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
MA49610A
(fr)
|
2016-12-08 |
2020-05-27 |
Univ Case Western Reserve |
Procédés et compositions pour améliorer la production de myéline fonctionnelle
|
AU2017376950B2
(en)
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
KR20190095412A
(ko)
|
2016-12-20 |
2019-08-14 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 게놈에서 상동성 지정 수복 (hdr)의 효율을 증가시키는 방법
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
KR102567845B1
(ko)
|
2017-01-31 |
2023-08-17 |
화이자 인코포레이티드 |
네이세리아 메닌기티디스 조성물 및 그의 방법
|
EP3634459A4
(de)
|
2017-02-10 |
2021-01-06 |
Washington University |
Antikörper gegen tip1 und verfahren zur verwendung davon
|
EP3585417B1
(de)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Methode der herstellung von codon-optimierter cftr-mrna
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
US11739308B2
(en)
|
2017-03-15 |
2023-08-29 |
The Broad Institute, Inc. |
Cas13b orthologues CRISPR enzymes and systems
|
IL269458B2
(en)
|
2017-03-23 |
2024-02-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
US10876101B2
(en)
|
2017-03-28 |
2020-12-29 |
Locanabio, Inc. |
CRISPR-associated (Cas) protein
|
AU2018251801A1
(en)
|
2017-04-12 |
2019-11-07 |
Massachusetts Institute Of Technology |
Novel type VI crispr orthologs and systems
|
TWI801377B
(zh)
|
2017-04-18 |
2023-05-11 |
美商阿尼拉製藥公司 |
治療具有b型肝炎病毒(hbv)感染之個體之方法
|
WO2018201091A1
(en)
|
2017-04-27 |
2018-11-01 |
Washington University |
Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof
|
US11596655B2
(en)
|
2017-04-27 |
2023-03-07 |
Washington University |
Activation of natural cytotoxicity receptor 2 (NCR2)
|
WO2018201090A1
(en)
|
2017-04-28 |
2018-11-01 |
Exicure, Inc. |
Synthesis of spherical nucleic acids using lipophilic moieties
|
WO2018208910A1
(en)
|
2017-05-09 |
2018-11-15 |
The Broad Institute Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
WO2018206732A1
(en)
|
2017-05-09 |
2018-11-15 |
Vib Vzw |
Means and methods for treating bacterial infections
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
CA3063531A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
US20210145907A1
(en)
|
2017-06-12 |
2021-05-20 |
Washington University |
Zika virus strains for treatment of glioblastoma
|
PT3538645T
(pt)
|
2017-06-20 |
2021-04-15 |
Inst Curie |
Células imunológicas deficitárias em suv39h1
|
CN111511906A
(zh)
|
2017-06-23 |
2020-08-07 |
因思科瑞普特公司 |
核酸引导性核酸酶
|
US20210093667A1
(en)
|
2017-06-26 |
2021-04-01 |
The Broad Institute, Inc. |
Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
KR20200028997A
(ko)
|
2017-07-13 |
2020-03-17 |
노오쓰웨스턴 유니버시티 |
올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
EP3661506A4
(de)
|
2017-07-31 |
2021-04-21 |
Washington University |
Pirfenidonderivate zur modulation von b-lymphozytenaktivität und organschutz
|
EP3668497A4
(de)
|
2017-08-14 |
2021-04-28 |
Washington University |
Verfahren und zusammensetzungen zur behandlung von mit krebs, entzündung oder immunreaktion assoziierten erkrankungen
|
EP3676376A2
(de)
|
2017-08-30 |
2020-07-08 |
President and Fellows of Harvard College |
Hocheffiziente baseneditoren mit gam
|
US11097018B2
(en)
|
2017-09-06 |
2021-08-24 |
Washington University |
Organomedicinals for imaging and treatment of neurodegenerative disorders
|
EP3684397A4
(de)
|
2017-09-21 |
2021-08-18 |
The Broad Institute, Inc. |
Systeme, verfahren und zusammensetzungen zur gezielten nukleinsäureeditierung
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
CN107827762B
(zh)
*
|
2017-11-14 |
2020-10-02 |
苏州东南药业股份有限公司 |
一种(2,3-二油酰基-丙基)三甲基氯化铵及其制备方法和用途
|
JP2021503281A
(ja)
|
2017-11-17 |
2021-02-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細針吸引及び小生検からのtil拡大培養
|
EP3714054A1
(de)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
|
EP3714041A1
(de)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion von peripheren blutlymphozyten (pbls) aus peripherem blut
|
TW201936201A
(zh)
|
2017-12-14 |
2019-09-16 |
美商堅固生物科技公司 |
基因之非病毒生產及遞送
|
US11597932B2
(en)
|
2017-12-21 |
2023-03-07 |
Alnylam Pharmaceuticals, Inc. |
Chirally-enriched double-stranded RNA agents
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
KR20200109358A
(ko)
|
2018-01-17 |
2020-09-22 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제
|
US20200353101A1
(en)
|
2018-01-17 |
2020-11-12 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
IL276081B2
(en)
|
2018-01-17 |
2023-10-01 |
Vertex Pharma |
Quinoxalinone compounds, preparations, methods and kits for increasing the efficiency of genome editing
|
CN112105360B
(zh)
|
2018-01-22 |
2024-01-30 |
生物风险投资有限责任公司 |
用于癌症治疗的bcl-2蛋白降解剂
|
MX2020007945A
(es)
|
2018-01-29 |
2020-09-24 |
Merck Sharp & Dohme |
Proteinas f del rsv estabilizadas y usos de las mismas.
|
CN108129338A
(zh)
*
|
2018-02-01 |
2018-06-08 |
爱斯特(成都)生物制药股份有限公司 |
一种阳性脂质体dotap的制备方法
|
WO2019160383A1
(ko)
|
2018-02-19 |
2019-08-22 |
고려대학교 산학협력단 |
열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
|
EP3539975A1
(de)
|
2018-03-15 |
2019-09-18 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Mikropeptide und verwendungen davon
|
EP3773505A4
(de)
|
2018-03-30 |
2021-12-22 |
Insmed Incorporated |
Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
EP3797160A1
(de)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Baseneditoren und verwendungen davon
|
SG11202011975WA
(en)
|
2018-06-05 |
2020-12-30 |
Lifeedit Inc |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
CA3106035A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Cas12b enzymes and systems
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
SG11202101169PA
(en)
|
2018-08-10 |
2021-03-30 |
Eutilex Co Ltd |
Chimeric antigen receptor that binds hla-dr and car-t cell
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
WO2020041793A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
CN113015741A
(zh)
|
2018-09-18 |
2021-06-22 |
桑格摩生物治疗股份有限公司 |
程序性细胞死亡1(pd1)特异性核酸酶
|
WO2020060986A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
WO2020069029A1
(en)
|
2018-09-26 |
2020-04-02 |
Emendobio Inc. |
Novel crispr nucleases
|
GB201815820D0
(en)
|
2018-09-28 |
2018-11-14 |
Univ Wageningen |
Off-target activity inhibitors for guided endonucleases
|
US20230048010A1
(en)
|
2018-09-28 |
2023-02-16 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
CA3116452A1
(en)
|
2018-10-15 |
2020-04-23 |
Fondazione Telethon |
Genome editing methods and constructs
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
WO2020096927A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
MX2021004953A
(es)
|
2018-11-05 |
2021-08-11 |
Iovance Biotherapeutics Inc |
Seleccion de celulas t reactivas al tumor mejoradas.
|
JOP20210094A1
(ar)
|
2018-11-05 |
2023-01-30 |
Iovance Biotherapeutics Inc |
عمليات لإنتاج الخلايا الليمفاوية للورم الارتشاحي واستخداماتها في العلاج المناعي
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
US20220056444A1
(en)
|
2018-12-05 |
2022-02-24 |
Empirico Inc. |
Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
|
EP3898958A1
(de)
|
2018-12-17 |
2021-10-27 |
The Broad Institute, Inc. |
Crispr-assoziierte transposase-systeme und verfahren zu deren verwendung
|
CA3123392A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
WO2020139783A2
(en)
|
2018-12-27 |
2020-07-02 |
Lifeedit, Inc. |
Polypeptides useful for gene editing and methods of use
|
WO2020150265A1
(en)
|
2019-01-15 |
2020-07-23 |
Empirico Inc. |
Prodrugs of alox-15 inhibitors and methods of using the same
|
WO2020163379A1
(en)
|
2019-02-05 |
2020-08-13 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
WO2020163017A1
(en)
|
2019-02-06 |
2020-08-13 |
Klogenix Llc |
Dna binding proteins and uses thereof
|
US20220154157A1
(en)
|
2019-02-06 |
2022-05-19 |
Emendobio Inc. |
New engineered high fidelity cas9
|
WO2020172343A2
(en)
|
2019-02-19 |
2020-08-27 |
Massachusetts Institute Of Technology |
Methods for treating injuries
|
CN113748202A
(zh)
|
2019-03-01 |
2021-12-03 |
艾欧凡斯生物治疗公司 |
由液体肿瘤扩增肿瘤浸润淋巴细胞及其治疗用途
|
EP3935083A4
(de)
|
2019-03-03 |
2022-11-30 |
Prothena Biosciences Limited |
Antikörper zur erkennung von tau
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
SG11202109225WA
(en)
|
2019-03-08 |
2021-09-29 |
Obsidian Therapeutics Inc |
Cd40l compositions and methods for tunable regulation
|
GB201903499D0
(en)
|
2019-03-14 |
2019-05-01 |
Ucl Business Plc |
Minimal promoter
|
US20220177863A1
(en)
|
2019-03-18 |
2022-06-09 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
WO2020191248A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Method and compositions for editing nucleotide sequences
|
CN113939586A
(zh)
|
2019-04-02 |
2022-01-14 |
桑格摩生物治疗股份有限公司 |
治疗β-地中海贫血症的方法
|
EP3953461A4
(de)
|
2019-04-09 |
2023-05-31 |
The Regents of The University of California |
Langanhaltende analgesie durch gezielte epigenetische unterdrückung in vivo
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
EP3956349A1
(de)
|
2019-04-17 |
2022-02-23 |
The Broad Institute, Inc. |
Adeninbaseneditoren mit reduzierten off-target-effekten
|
US20220175723A1
(en)
|
2019-04-22 |
2022-06-09 |
The Penn State Research Foundation |
Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer
|
WO2020223539A1
(en)
|
2019-04-30 |
2020-11-05 |
The Broad Institute, Inc. |
Methods and compositions for barcoding nucleic acid libraries and cell populations
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
WO2020232271A1
(en)
|
2019-05-14 |
2020-11-19 |
The Broad Institute, Inc. |
Compositions and methods for targeting multinucleated cells
|
US20220211743A1
(en)
|
2019-05-17 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
WO2020236982A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Aav delivery of nucleobase editors
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
US20210317192A9
(en)
|
2019-05-29 |
2021-10-14 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
CN114040976A
(zh)
|
2019-05-29 |
2022-02-11 |
奥驰亚客户服务有限公司 |
用于产生烟杈减少或消除的烟草植物和产品的组合物和方法
|
GB201909597D0
(en)
|
2019-07-03 |
2019-08-14 |
Univ Wageningen |
Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof
|
CN114222815A
(zh)
|
2019-07-23 |
2022-03-22 |
记忆疗法公司 |
Suv39h1缺陷的免疫细胞
|
WO2021025750A1
(en)
|
2019-08-08 |
2021-02-11 |
The Broad Institute, Inc. |
Base editors with diversified targeting scope
|
AU2020329912A1
(en)
|
2019-08-12 |
2022-03-24 |
LifeEDIT Therapeutics, Inc. |
RNA-guided nucleases and active fragments and variants thereof and methods of use
|
EP4013870A1
(de)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
CN115023499A
(zh)
|
2019-08-16 |
2022-09-06 |
麻省理工学院 |
使用CRISPR/Cas13的靶向反式剪接
|
KR102099342B1
(ko)
|
2019-09-03 |
2020-04-10 |
주식회사 제노포커스 |
Crm197 단백질 발현 방법
|
CN114745946B
(zh)
|
2019-10-10 |
2024-03-08 |
奥驰亚客户服务有限公司 |
浅黄色基因座及其在烟草中的应用
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
TW202132566A
(zh)
|
2019-11-01 |
2021-09-01 |
美商聖加莫治療股份有限公司 |
用於治療或預防溶體貯積病之鋅指核酸酶變異體
|
AR120341A1
(es)
|
2019-11-01 |
2022-02-09 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
EP4055167A2
(de)
|
2019-11-08 |
2022-09-14 |
Phio Pharmaceuticals Corp. |
Auf das bromodomainhaltige protein 4 (brd4) abzielende chemisch modifizierte oligonukleotide für die immuntherapie
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
JP2023506734A
(ja)
|
2019-12-11 |
2023-02-20 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球(til)の産生のためのプロセス及びそれを使用する方法
|
EP4073251A1
(de)
|
2019-12-13 |
2022-10-19 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen des open reading frame 72 (c9orf72) des menschlichen chromosoms 9 und verfahren zu ihrer verwendung
|
CA3164996A1
(en)
|
2019-12-20 |
2021-06-14 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
CN115190912A
(zh)
|
2019-12-30 |
2022-10-14 |
生命编辑制药股份有限公司 |
Rna指导核酸酶及其活性片段与变体以及使用方法
|
WO2021138537A1
(en)
|
2019-12-31 |
2021-07-08 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
WO2021142376A1
(en)
|
2020-01-08 |
2021-07-15 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
GB202000934D0
(en)
|
2020-01-22 |
2020-03-04 |
Ucl Business Ltd |
Engineered immune cells
|
WO2021155065A1
(en)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
EP4100032A1
(de)
|
2020-02-05 |
2022-12-14 |
The Broad Institute Inc. |
Geneditierungsverfahren zur behandlung von spinaler muskelatrophie
|
WO2021158921A2
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
WO2021163191A1
(en)
|
2020-02-10 |
2021-08-19 |
Board Of Regents, The University Of Texas System |
Methods for rapid cloning and expression of hla class i cells
|
US20230123584A1
(en)
|
2020-02-14 |
2023-04-20 |
Merck Sharp & Dohme Llc |
Hpv vaccine
|
US11752199B1
(en)
|
2020-02-25 |
2023-09-12 |
Mallinckrodt Ard Ip Unlimited Company |
Methods of modulating pericytes
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
EP3885440A1
(de)
|
2020-03-26 |
2021-09-29 |
Splicebio, S.L. |
Spaltinteine und deren verwendungen
|
CN116209759A
(zh)
|
2020-03-26 |
2023-06-02 |
阿尔尼拉姆医药品有限公司 |
冠状病毒iRNA组合物及其使用方法
|
EP4133077A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202208626A
(zh)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna引導核酸酶及其活性片段與變體,以及使用方法
|
KR20230018377A
(ko)
|
2020-04-27 |
2023-02-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
|
WO2021222318A1
(en)
|
2020-04-28 |
2021-11-04 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
EP4146794A1
(de)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Verfahren zur herstellung von tumorinfiltrierenden lymphozyten und verwendungen davon in der immuntherapie
|
CN111393595A
(zh)
*
|
2020-05-06 |
2020-07-10 |
东莞市竤穗实业投资有限公司 |
一种具有温敏特性的生物基聚碳化二亚胺交联剂及其制备方法
|
WO2021224395A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
WO2021224416A1
(en)
|
2020-05-06 |
2021-11-11 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
WO2021231437A1
(en)
|
2020-05-11 |
2021-11-18 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
|
EP4150090A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150078A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
|
EP4150077A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
|
EP4150089A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
BR112022023366A2
(pt)
|
2020-05-19 |
2023-05-02 |
Othair Prothena Ltd |
Vacina com múltiplos epítopos para o tratamento de mal de alzheimer
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
BR112023000428A2
(pt)
|
2020-07-10 |
2023-03-14 |
Inst Nat Sante Rech Med |
Métodos e composições para tratar epilepsia
|
IL299812A
(en)
|
2020-07-15 |
2023-03-01 |
Lifeedit Therapeutics Inc |
Uracil stabilizing proteins and active fragments and their variants and methods of use
|
JP2023535501A
(ja)
|
2020-07-30 |
2023-08-17 |
アンスティテュ・クリー |
Socs1に欠陥のある免疫細胞
|
WO2022034374A2
(en)
|
2020-08-11 |
2022-02-17 |
University Of Oslo |
Improved gene editing
|
US20220064596A1
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
WO2022051591A2
(en)
|
2020-09-04 |
2022-03-10 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
EP4211235A2
(de)
|
2020-09-11 |
2023-07-19 |
Lifeedit Therapeutics, Inc. |
Dna-modifizierende enzyme und aktive fragmente sowie varianten davon und verfahren zur verwendung
|
WO2022060927A1
(en)
|
2020-09-17 |
2022-03-24 |
Northwestern University |
Engineered mammalian genetic circuits and methods of using the same
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP3973978A1
(de)
|
2020-09-25 |
2022-03-30 |
Mallinckrodt Ard IP Unlimited Company |
Verfahren zur modulation der corticosteroid-reaktion
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4225330A1
(de)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
|
US20230390371A1
(en)
|
2020-10-16 |
2023-12-07 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Anti-tumor immunity induces the presentation of aberrant peptides
|
EP4232581A1
(de)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4251170A1
(de)
|
2020-11-25 |
2023-10-04 |
Akagera Medicines, Inc. |
Lipidnanopartikel zur abgabe von nukleinsäuren und zugehörige verfahren zur verwendung
|
TW202237150A
(zh)
|
2020-12-01 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
用於抑制hao1(羥基酸氧化酶1(乙醇酸氧化酶))基因表現的方法及組成物
|
EP4262827A1
(de)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Behandlung von krebs mit tumorinfiltrierenden lymphozyten
|
WO2022133140A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
JP2024503437A
(ja)
|
2021-01-11 |
2024-01-25 |
ザ ブロード インスティテュート,インコーポレーテッド |
プライム編集効率及び精度を向上させるためのプライム編集因子バリアント、構築物、及び方法
|
EP4284925A1
(de)
|
2021-01-26 |
2023-12-06 |
California Institute of Technology |
Allosterische bedingte guide-rnas zur zellselektiven regulierung von crispr/cas
|
EP4284923A1
(de)
|
2021-01-29 |
2023-12-06 |
Wageningen Universiteit |
Crispr-assoziierte baseneditierung des komplementären strangs
|
JP2024505756A
(ja)
|
2021-02-03 |
2024-02-07 |
アルトリア クライアント サーヴィシーズ リミテッド ライアビリティ カンパニー |
植物毛状突起における毛状突起密度の増加および代謝物の輸送の改善の方法
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
WO2022174000A2
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プリオンタンパク質(prnp)irna組成物およびその使用方法
|
EP4304637A1
(de)
|
2021-03-12 |
2024-01-17 |
Synthego Corporation |
Genetisch modifizierte zellen zur expression antigenhaltiger fusionsproteine und verwendungen davon
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
TW202300649A
(zh)
|
2021-03-22 |
2023-01-01 |
美商生命編輯治療學公司 |
Dna修飾酶及活性片段及其變體及使用方法
|
CA3214499A1
(en)
|
2021-03-29 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
IL307800A
(en)
|
2021-04-19 |
2023-12-01 |
Iovance Biotherapeutics Inc |
Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy
|
WO2022226291A1
(en)
|
2021-04-22 |
2022-10-27 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4341401A1
(de)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CA3218475A1
(en)
|
2021-05-21 |
2022-11-24 |
Shipra DAS |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
BR112023025224A2
(pt)
|
2021-06-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
|
CA3173953A1
(en)
|
2021-06-11 |
2023-12-10 |
Tyson D. BOWEN |
Rna polymerase iii promoters and methods of use
|
WO2022261509A1
(en)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2023288285A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Polycistronic expression vectors
|
WO2023288288A1
(en)
|
2021-07-15 |
2023-01-19 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
|
US20230044997A1
(en)
|
2021-07-15 |
2023-02-09 |
Turn Biotechnologies, Inc. |
Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
|
IL309905A
(en)
|
2021-07-23 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions in β-catenin (CTNNB1) and methods of using them
|
GB202110644D0
(en)
|
2021-07-23 |
2021-09-08 |
Sisaf Ltd |
Improved nucleic acid vector particles
|
GB202110646D0
(en)
|
2021-07-23 |
2021-09-08 |
Sisaf Ltd |
Nucleic acid vector compositions
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
WO2023015265A2
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides
|
AU2022325166A1
(en)
|
2021-08-06 |
2024-02-08 |
President And Fellows Of Harvard College |
Improved prime editors and methods of use
|
AU2022331279A1
(en)
|
2021-08-19 |
2024-02-15 |
Merck Sharp & Dohme Llc |
Thermostable lipid nanoparticle and methods of use thereof
|
CA3233460A1
(en)
|
2021-10-01 |
2023-04-06 |
Jeroen Petrus Wilhelmus Maria BAKKERS |
Mammalian cardiac regeneration
|
WO2023069603A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023069498A1
(en)
|
2021-10-22 |
2023-04-27 |
Senda Biosciences, Inc. |
Mrna vaccine composition
|
WO2023076898A1
(en)
|
2021-10-25 |
2023-05-04 |
The Broad Institute, Inc. |
Methods and compositions for editing a genome with prime editing and a recombinase
|
US20230187042A1
(en)
|
2021-10-27 |
2023-06-15 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
CN114015674A
(zh)
|
2021-11-02 |
2022-02-08 |
辉二(上海)生物科技有限公司 |
新型CRISPR-Cas12i系统
|
WO2023080788A1
(en)
|
2021-11-05 |
2023-05-11 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023096858A1
(en)
|
2021-11-23 |
2023-06-01 |
Senda Biosciences, Inc. |
A bacteria-derived lipid composition and use thereof
|
WO2023096494A1
(en)
|
2021-11-26 |
2023-06-01 |
Synvolux Ip B.V. |
Conserved coronavirus t cell epitopes
|
WO2023122080A1
(en)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023139557A1
(en)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023150637A1
(en)
|
2022-02-02 |
2023-08-10 |
Inscripta, Inc. |
Nucleic acid-guided nickase fusion proteins
|
WO2023196802A1
(en)
|
2022-04-04 |
2023-10-12 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023212715A1
(en)
|
2022-04-28 |
2023-11-02 |
The Broad Institute, Inc. |
Aav vectors encoding base editors and uses thereof
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023220459A1
(en)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Active loading of cargo entity into lipid bilayer particles using dimerization domains
|
WO2023220392A1
(en)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Synthetic modular extracellular sensors that employ natural receptor ligand-binding domains
|
WO2023220457A1
(en)
|
2022-05-13 |
2023-11-16 |
Northwestern University |
Receptor engagement-mediated enhancement of biologics delivery
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
EP4279085A1
(de)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Zusammensetzungen und verfahren zum behandeln eines refraktären oder rezidivierenden krebses oder einer chronischen infektionskrankheit
|
WO2023230433A1
(en)
|
2022-05-23 |
2023-11-30 |
Altria Client Services Llc |
Methods and compositions for regulating alkaloids in tobacco field
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
US20230392188A1
(en)
|
2022-06-02 |
2023-12-07 |
Perkinelmer Health Sciences, Inc. |
Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids
|
WO2023235818A2
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
WO2023240076A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023240074A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024015383A1
(en)
|
2022-07-12 |
2024-01-18 |
Northwestern University |
Engineered hypoxia biosensors and methods of using the same
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031038A1
(en)
|
2022-08-05 |
2024-02-08 |
Altria Client Services Llc |
Methods and compositions for regulating alkaloids in tobacco
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|